

10580530.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 FEB 02 Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 4 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 5 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 6 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 7 FEB 11 WTEXTILES reloaded and enhanced  
NEWS 8 FEB 19 New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art  
NEWS 9 FEB 19 Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01  
NEWS 10 FEB 23 Several formats for image display and print options discontinued in USPATFULL and USPAT2  
NEWS 11 FEB 23 MEDLINE now offers more precise author group fields and 2009 MeSH terms  
NEWS 12 FEB 23 TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms  
NEWS 13 FEB 23 Three million new patent records blast AEROSPACE into STN patent clusters  
NEWS 14 FEB 25 USGENE enhanced with patent family and legal status display data from INPADOCDB  
NEWS 15 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display formats  
NEWS 16 MAR 11 EPFULL backfile enhanced with additional full-text applications and grants  
NEWS 17 MAR 11 ESBIOBASE reloaded and enhanced  
NEWS 18 MAR 20 CAS databases on STN enhanced with new super role for nanomaterial substances  
NEWS 19 MAR 23 CA/CAplus enhanced with more than 250,000 patent equivalents from China  
NEWS 20 MAR 30 IMSPATENTS reloaded and enhanced  
NEWS 21 APR 03 CAS coverage of exemplified prophetic substances enhanced  
NEWS 22 APR 07 STN is raising the limits on saved answers  
NEWS 23 APR 24 CA/CAplus now has more comprehensive patent assignee information  
NEWS 24 APR 26 USPATFULL and USPAT2 enhanced with patent assignment/reassignment information  
NEWS 25 APR 28 CAS patent authority coverage expanded  
NEWS 26 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced  
NEWS 27 APR 28 Limits doubled for structure searching in CAS REGISTRY

10580530.trn

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

**NEWS HOURS** STN Operating Hours Plus Help Desk Availability  
**NEWS LOGIN** Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:30:01 ON 06 MAY 2009

$\Rightarrow$

## Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n) :

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 18:30:22 ON 06 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7  
DICTIONARY FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7

FOR THIS INFORMATION USE POLICIES, CHECK REED CATALOGUE FOR DETAILS.

ISCA INFORMATION NOW CURRENT THROUGH January 5, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

$\Rightarrow$

10580530.trn

Uploading C:\Program Files\Stnexp\Queries\10580530-44.str



chain nodes :

13 14 16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ring/chain nodes :

15 20

chain bonds :

1-7 8-13 13-14 13-15 14-16 14-20 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

13-14 13-15 14-16 16-17

exact bonds :

1-7 8-13 14-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 20:CLASS

Generic attributes :

16:

Saturation : Unsaturated

Type of Ring System : Monocyclic

Element Count :

Node 16: Limited

C,C3-10

O,O0

S,S0

N,N0-3

Node 17: Limited


C,C4-5

N,N1-2

10580530.trn

L1 STRUCTURE UPLOADED

=>  
Uploading C:\Program Files\Stnexp\Queries\10580530-45.str



chain nodes :  
13 14 16 17  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12  
ring/chain nodes :  
15 20  
chain bonds :  
1-7 8-13 13-14 13-15 14-16 14-20 16-17  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
exact/norm bonds :  
13-14 13-15 14-16 16-17  
exact bonds :  
1-7 8-13 14-20  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12  
  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 20:CLASS  
Generic attributes :  
16:  
Saturation : Unsaturated  
Type of Ring System : Monocyclic  
17:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic  
  
Element Count :  
Node 16: Limited  
C,C3-10  
O,O0  
S,S0


10580530.trn

N,N0-3

Node 17: Limited  
C,C4-5  
N,N1-2

L2 STRUCTURE UPLOADED

=> d 12  
L2 HAS NO ANSWERS  
L2 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 12  
SAMPLE SEARCH INITIATED 18:31:11 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4981 TO ITERATE

40.2% PROCESSED 2000 ITERATIONS 3 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 95388 TO 103852  
PROJECTED ANSWERS: 3 TO 313

L3 3 SEA SSS SAM L2

=> d scan

10580530.trn


L3 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1(2H)-Pyridineacetamide,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl)amino]phenyl]-  
3,6-dihydro- $\alpha$ -phenyl-N-2-propen-1-yl-  
MF C35 H33 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN [1,1'-Biphenyl]-2-carboxamide, 2'-chloro-N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-6-methyl-2-pyrimidinyl)phenyl]-  
MF C26 H22 Cl2 F3 N3 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN [1,1'-Biphenyl]-2-carboxamide,  
2'-chloro-N-[2-methyl-6-(1,4,5,6-tetrahydro-  
1-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)-  
MF C26 H23 Cl F3 N3 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10580530.trn

=> s l2 full  
FULL SEARCH INITIATED 18:31:27 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 99973 TO ITERATE

100.0% PROCESSED 99973 ITERATIONS 39 ANSWERS  
SEARCH TIME: 00.00.11



L4 39 SEA SSS FUL L2

=> file caplus  
FILE 'CAPLUS' ENTERED AT 18:31:41 ON 06 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 2008:1483375 Document No. 150:354010 Preparation of piperidine/piperazine derivatives as DGAT inhibitors. Bongartz, Jean-Pierre Andre Marc; Linders, Joannes Theodorus Maria; Meerpoel, Lieven; Van Lommens, Guy Rosalia Eugeen; Coesmans, Erwin; Braeken, Mirielie; Buyck, Christophe Francis Robert Nestor; Berwae, Monique Jenny Marie; De Waepenaert, Katharina Antonia Germania J. M.; Roeven, Peter Walter Maria; Vlidenko, Petr Vladimirovich (Janssen Pharmaceutica N.V., Belg.) PCT Int. Appl.  
 WO 2008148849 A2 20081211, 128pp. DESIGNATED STATES: W, AE, AG, AL, AM,  
 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ,  
 DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,  
 LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
 OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ,  
 TM, TN, TR, TT; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES,  
 FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE,  
 SN, TD, TG, TR. (English) CODEN: FIXXD2. APPLICATION: WO 2008-EP57008  
 20080605. PRIORITY: EP 2007-109866 20070608.

GI



II

AB The title compds. I [A = CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X = OC(O), C(O)C(O), ZC(O), C(O)Z, etc. (Z = (un)substituted alkenediyl, alkenediyl, alkynediyl); R1 = adamantlyl, cycloalkyl, (un)substituted (hetero)aryl; Y = C(O)NRx or NRxC(O) (wherein Rx = H or alkyl; Z2 = (un)substituted alkenediyl, alkenediyl, alkynediyl); R2 = (un)substituted cycloalkyl, Ph, naphthalenyl, etc.; R7 = H, halo, alkyl, hydroxalkyl, useful as DGAT inhibitors, were prepared and formulated. E.g., a multi-step synthesis of

of II, starting from 1,1-dimethylethyl [4-(4-piperidinyl)phenyl]carbamate and 1,3-dichloro-2-isocyanatobenzene, was given. Exemplified compds. I were

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 tested for inhibition of DGAT1. For example, II showed pIC50 of 8.09. The invention further relates to methods for prepg. compds. I, pharmaceutical compns. comprising said compds. as well as the use as a medicine of said compds.

IT 1092504-27-2P 1092504-28-3P 1092504-29-4P


1092504-30-7P 1092504-31-8P 1092504-32-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine/piperazine derivs. as DGAT inhibitors)


RN 1092504-27-2 CAPLUS

CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-propyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092504-28-3 CAPLUS


CN 1(2H)-Pyridinecarboxamide, N-(cyclohexylmethyl)-3,6-dihydro-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092504-29-4 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-(phenylmethyl)-4-[4-[(4'-

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092504-30-7 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-(3-phenylpropyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092504-31-8 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-[(4-methoxyphenyl)methyl]-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1092504-32-9 CAPLUS

CN 1(2H)-Pyridinecarboxamide, N-[(4-(dimethylamino)phenyl)-3,6-dihydro-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



IT 403987-66-6P 1092504-59-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidine/piperazine derivs. as DGAT inhibitors)


RN 403987-66-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide,  
 N-[4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-

pyridinyl]phenyl]-4'-trifluoromethyl- (CA INDEX NAME)



RN 1092504-59-0 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-4'-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states assoc. with unwanted angiogenesis and/or cellular proliferation, by administering effective amt. of such compds.


IT 625468-52-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of protein kinase modulators)  
RN 625468-52-2 CAPLUS  
CN 2-Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN 2003:892800 Document No. 139:3959500 Preparation of substituted pyrazines as protein kinase modulators. Bahr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Bailli; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Petro, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepp, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Larry Wayne; Takeuchi, Craig Stacy (Exelixis, Inc., USA). PCT Int. Appl. WO 2003093297 A2 20031113, 468 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LB, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, OM, PB, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YE, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US13869 20030502. PRIORITY: US 2002-377933P 20020503.


GI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH2; A = CO, CS, C(:NR6), R7 (When A = R7, E does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heterocyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with provisos] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 678 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN 2003:154424 Document No. 138:2050570 Preparation of N-[2-(heteroaryl)phenyl]pyrazole-5-carboxamides for controlling invertebrate pests. Clark, David Alan; Finkelstein, Bruce Lawrence; Lahm, George Philip; Selby, Tom Paul; Stevenson, Thomas Martin (E. I. Du Pont de Nemours & Co., USA). PCT Int. Appl. WO 2003016304 A1 20030227, 172 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, PL, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UG, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US26968 20020812. PRIORITY: US 2001-312440P 20010815.

GI



AB The title compds. [I; A = O, S; G = (un)substituted 5-6 membered heteroarom. ring or a 5-6 membered nonarom. heterocyclic ring optionally including one or two ring members selected from the group consisting of CO, SO or SO2; J = (un)substituted Ph, a 5-6 membered heteroarom. ring or an aromatic 8-10 membered fused carbocyclic or heterocyclic ring system;

RL = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; n = 1-4; useful for controlling an invertebrate pest, were prepared. Thus, treating 1-(3-chloro-2-pyridinyl)-3-trifluoromethyl-1H-pyrazole-5-carboxylic acid with (COCl)2 in CH2Cl2 followed by addition of a solution of 4-bromo-2-(4,5-dihydro-1H-imidazol-2-yl)-6-methylbenzamine (3-step preparation given), DMAP and Et3N in CH2Cl2 afforded II which provided excellent levels of plant protection (20% or less feeding damage) when tested at 50 ppm.


IT 1064406-05-8 1064406-11-6 1064406-12-7  
1064406-14-9 1064406-18-3 1064406-19-4  
1064406-20-7 1064406-23-3 1064406-25-2  
1064406-26-3 1064406-31-1 1064406-32-1  
1064406-34-3 1064406-38-7 1064406-40-1  
1064406-41-2 1064406-91-2 1064406-92-3  
1064406-97-8 1064406-98-9

RL: PRPH (Prophetic)  
(Preparation of N-[2-(heteroaryl)phenyl] pyrazole-5-carboxamides for controlling invertebrate pests)


RN 1064406-05-8 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide,  
N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-

10580530.trn


L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 6,6-dimethyl-2-pyrimidinylphenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 1064406-11-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 2'-chloro-N-[2-chloro-6-(1,4,5,6-tetrahydro-  
 6,6-dimethyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-12-7 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 2'-chloro-N-[2-methyl-6-(1,4,5,6-tetrahydro-  
 6,6-dimethyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-14-9 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 2'-chloro-N-[4-chloro-2-methyl-6-(1,4,5,6-


L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 tetrahydro-6,6-dimethyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 1064406-18-3 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 2',5-dichloro-N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-6-methyl-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 1064406-19-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 5-bromo-2'-chloro-6-(1,4,5,6-tetrahydro-6-methyl-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 1064406-20-7 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-  
 6-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 1064406-23-0 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 2'-chloro-N-[2-chloro-6-(1,4,5,6-tetrahydro-  
 6-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-25-2 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 2'-chloro-N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-6-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-26-3 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 2'-chloro-N-[2-methyl-6-(1,4,5,6-tetrahydro-


L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 6-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-31-0 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 2',5-dichloro-N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 1064406-32-1 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, 5-bromo-2'-chloro-N-[2-chloro-6-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 1064406-34-3 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 N-[4-chloro-2-methyl-6-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-38-7 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide,  
2'-chloro-N-[2-chloro-6-(1,4,5,6-tetrahydro-  
2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)





RN 1064406-40-1 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide,  
2'-chloro-N-[2-methyl-6-(1,4,5,6-tetrahydro-  
2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-41-2 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, 2'-chloro-N-[4-chloro-2-methyl-6-(1,4,5,6-  
tetrahydro-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 1064406-98-9 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, 5-bromo-2'-chloro-N-[2-chloro-6-(1,4,5,6-  
tetrahydro-6,6-dimethyl-2-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 1064406-91-2 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, 2'-chloro-N-[4-chloro-2-methyl-6-(1,4,5,6-  
tetrahydro-1-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 1064406-92-3 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide,  
2'-chloro-N-[2-methyl-6-(1,4,5,6-tetrahydro-  
1-methyl-2-pyrimidinyl)phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 1064406-97-8 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, 2',5-dichloro-N-[4-chloro-2-methyl-6-  
(1,4,5,6-tetrahydro-6,6-dimethyl-2-pyrimidinyl)phenyl]- (CA INDEX NAME)

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
2002-793613 Document No. 137:3109340 Preparation of piperidinyl-,  
piperazinylcarboxamides as lipid lowering agents. Meerpoel, Lieven;  
Viellevoye, Marcel (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl.  
WO 2002081460 A1 20020107, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CS, DE, DK, DM,  
DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KW, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN,  
TR, TT, TZ, US, UG, US, UZ, VR, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI,  
FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.  
(English). CODEN: PIIXDZ. APPLICATION: WO 2002-EP3491 20020327.  
PRIORITY: EP 2001-201270 20010406.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [r,s,q = 1-3; p = 0-1; R1 = H, alkyl, alkyloxy, halo, hydroxy, mercapto, cyano, nitro, etc.; R2 = H, alkyl, alkyloxy, halo, CF3; R3 = H, alkyl, R4 = alkyl, alkyloxy, halo, CF3; Z = e.g., -X1(R5)-(CH2)n-X2(R6)-; n = 2-4; R5-6 = H, alkyl, aryl; X1-2 = CH, N, sp2 hybridized carbon, etc.; A = bond, alkanediyl, etc.; B = e.g., R8-OCO-alkanediyl-Y; Y = O, amino, etc.; R8 = alk(en/yn)yl, etc.] were prepared. For instance, N-[4-(1-piperazinyl)phenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (preparation given) was reacted with α-chlorobenzenoacetic acid 2-methoxy-2-oxoethyl ester (preparation given, DMF, Na2CO3) to afford, after purification, II, m.p. 106°. II inhibited microsomal triglyceride transfer protein (MTP) activity with pIC50 = 6.591. I are useful for the treatment of hyperlipidemia, obesity and type II diabetes.


IT 403987-66-6P, N-[4-[1,2,3,6-Tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide 403987-67-7P, N-[4-(1,2,3,6-Tetrahydro-4-pyridinyl)phenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of amidomethylpiperidinyl/piperazinyl-aryl-carboxamides

as lipid lowering agents)


RN 403987-66-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide,  
N-[4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)





RN 403987-67-7 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
2002-275966 Document No. 136:2947390 Preparation of pyridinyl-substituted benzamides as Apo B secretase inhibitors. Takasugi, Hisashi; Terazawa, Takehi; Inoue, Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Otake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto (Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.). PCT Int. Appl. WO 2002028835 A1 20020411, 266 pp. DESIGNATED STATES: W; AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PB, PL, PT, RO, RU, SD, RW, AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-JP8581 20010928. PRIORITY: AU 2000-583 20001005; AU 2001-6666 20010727.

GI



II

AB Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO2, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)m(A2)n(A4)k; Z = direct bond, CH2, NH, or O; R = H or alkyl; A1 = (un)substituted alkylene or alkynylene; A2 = NR3, CONR3, NHCONH, CO2, O, O(CH2)2NR3, S, SO, or SO2; A4 = alkylene, alkenylene, or alkynylene; R3 = H or suitable substituent; k, m, and n = independently 0


L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

secretion or 1; or a salt thereof] were prep'd. as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid-HCl, and HOBT·H2O in CH2Cl2 was added to WSCeHCl, followed by TEA at 5°C. The mixt. was stirred at room temp. for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10-6 M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglycerideridemia, atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus, obesity, coronary heart disease, myocardial infarction, stroke, restenosis, and Syndrome X.

IT 408365-05-9P, N-[4-(2-Pyridinyl)phenyl]-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Apo B inhibitor; preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)


RN 408365-05-9 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(2-pyridinyl)phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
2002-185098 Document No. 136:2476080 Preparation of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcarboxamides as lipid lowering agents. Meerpoel, Lieven; Koeven, Peter Walter Maria; Backx, Leo Jacobus Jozef; Van der Veken, Louis Jozef Elisabeth; Vieillevoye, Marcel (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2002020501 A2 20020314,

105 pp. DESIGNATED STATES: W; AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9926 20010827. PRIORITY: EP 2000-203067 20000904.

GI



AB Title compds. [I; Z1 = (CH2)n, CH2CH2O; n = 1-3; Z2 = (CH2)m; m = 1, 2; X1 = O, CH2, CO, NH, CH2O, CH2S, bond; X2, X3 = CH, N, C; R1 = H, alkyl; Ar1, Ar2 = (substituted) Ph, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolyl, furyl, thiényl; R2, R3 = alkyl, alkoxy, halo, CF3; R4 = alkyl, alkoxy, halo, SH, cyano, NO2, alkylthio, polyhaloalkyl, amino, alkylamino, dialkylamino; p, pp = 0-2; ppp = 0-3; X1, R4 taken together with Ar1 and Ar2 to which they are attached = fluoren-1-yl, fluoren-4-yl; A = alkanediyl substituted with 1-2 aryl, heteroaryl, cycloalkyl; when X3 = CH, A may also = N substituted with H, alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl; B = H, alkyl, aralkyl, heteroarylalkyl, (substituted) aryl, heteroaryl, etc.], and N-oxides thereof, were prepared Thus, 4'-trifluoromethylbiphenyl-2-carboxylic acid was stirred 2 h with (COCl)2 in CH2Cl2 containing DMF; the resulting mixture was added to a mixture prepared from

4-(4-aminophenyl)- $\alpha$ -Ph-N-(2,2,2-trifluoroethyl)-1-piperazineacetamide (preparation given) and Et3N in CH2Cl2 under ice/salt cooling followed by stirring and reflux for 2 days to give N-[4-(2-oxo-1-phenyl-2-[2,2,2-trifluoroethyl]aminoethyl)-1-piperazinylphenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide. The latter inhibited microsomal triglyceride transfer protein (MTP) activity with pIC50 = 7.864.

IT 403989-13-9 403989-21-9 403989-23-0


403989-23-0 403989-24-2 403989-25-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcarboxamides as lipid lowering agents)


RN 403989-13-9 CAPLUS

## 10580530.trn


L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 1(2H)-Pyridineacetic acid, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-3,6-dihydro- $\alpha$ -phenyl-, methyl ester (CA INDEX NAME)



RN 403989-21-9 CAPLUS  
 CN 1(2H)-Pyridineacetamide, 3,6-dihydro- $\alpha$ -diphenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403989-22-0 CAPLUS  
 CN 1(2H)-Pyridineacetamide, 3,6-dihydro- $\alpha$ -phenyl-N-2-propen-1-yl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403989-23-1 CAPLUS

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 (prepn. of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcarboxamides as lipid lowering agents)


RN 403987-57-5 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 N-[4-(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 403987-66-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide,  
 N-[4-(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl)phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 403987-67-7 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 403987-68-8 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(1,2,3,6-tetrahydro-4-


L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 1(2H)-Pyridineacetamide,  
 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-3,6-dihydro- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 403989-24-2 CAPLUS  
 CN 1(2H)-Pyridineacetamide,  
 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-3,6-dihydro- $\alpha$ -phenyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 403989-25-3 CAPLUS  
 CN 1(2H)-Pyridineacetic acid, 3,6-dihydro- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, phenylmethyl ester (CA INDEX NAME)



IT 403987-57-5P 403987-66-6P 403987-67-7P  
 403987-68-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 pyridinyl)phenyl]- (CA INDEX NAME)



RN 403987-68-8 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxamide, N-[4-(1,2,3,6-tetrahydro-4-

10580530.trn

=> file reg  
FILE 'REGISTRY' ENTERED AT 18:33:00 ON 06 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7  
DICTIONARY FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

10580530.trn

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

13-14 13-15 14-16 16-17

exact bonds :

1-7 8-13 14-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 20:CLASS

Generic attributes :

16:

Saturation : Unsaturated

Type of Ring System : Monocyclic

17:

Saturation : Saturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :


Node 16: Limited

C,C3-10

O,OO

S,SO


10580530.trn



Structure attributes must be viewed using STN Express query preparation.

10580530.trn


L7 22 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Butanoic acid, 4-[(2-phenyl-2-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino)phenyl]-1-piperazinyl]acetyl]amino-, methyl ester  
 MF C37 H37 F3 N4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L7 22 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperidinecarboxamide, N-(2-chloro-6-methylphenyl)-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-  
 MF C33 H29 Cl F3 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L7 22 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperazineacetic acid, 4-[3,5-difluoro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl-, methyl ester  
 MF C33 H28 F5 N3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 22 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 4-Piperidineacetic acid, 1-[4-[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, ethyl ester  
 MF C30 H31 F3 N2 O3





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10580530.trn

=>  
Uploading C:\Program Files\Stnexp\Queries\10580530-sat.str



10580530.trn

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 20:CLASS

21:CLASS 22:CLASS 24:CLASS 25:CLASS

Generic attributes :

16:

Saturation : Unsaturated

Type of Ring System : Monocyclic

17:

Saturation : Saturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 16: Limited

C,C3-10

O,OO

S,SO


N,N0-3

Node 17: Limited

C,C4-5

N,N1-2

10580530.trn




G1 O, S, N

Structure attributes must be viewed using STN Express query preparation.


10580530.trn

L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperazineacetic acid,  
 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-  
 α-phenyl-, 2-methoxy-2-oxoethyl ester compd. with 2-propanol,  
 hydrochloride (1:1:2)  
 MF C34 H33 N3 O5 . C3 H8 O . 2 Cl H

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Butanoic acid,  
 4-[(2-phenyl-2-[4-[[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperazinyl]acetyl]amino]-, methyl ester  
 MF C37 H37 F3 N4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 4-Piperidineacetic acid, 1-[4-[[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester  
 MF C30 H31 F9 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperidinecarboxamide, N-(2-ethylphenyl)-4-[(4-((trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl)amino]phenyl]-  
 MF C34 H32 F3 N3 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10580530.trn


L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperidinecarboxamide, N-(2-chloro-6-methylphenyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-  
 MF C33 H29 Cl F3 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 4-Piperidineacetamide, 1-[4-[[[4'-chloro[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-  
 MF C35 H36 Cl N3 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (+)-  
 MF C34 H31 F3 N2 O3


Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 13 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1H-benzimidazol-2-ylmethyl ester  
 MF C41 H35 F3 N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10580530.trn

=> d his

(FILE 'HOME' ENTERED AT 18:30:01 ON 06 MAY 2009)

FILE 'REGISTRY' ENTERED AT 18:30:22 ON 06 MAY 2009

L1           STRUCTURE UPLOADED  
L2           STRUCTURE UPLOADED  
L3           3 S L2  
L4           39 S L2 FULL

FILE 'CAPLUS' ENTERED AT 18:31:41 ON 06 MAY 2009

L5           6 S L4

FILE 'REGISTRY' ENTERED AT 18:33:00 ON 06 MAY 2009

L6           STRUCTURE UPLOADED  
L7           22 S L6  
L8           STRUCTURE UPLOADED  
L9           13 S L8


=> s 18

SAMPLE SEARCH INITIATED 18:37:06 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -       4393 TO ITERATE

45.5% PROCESSED      2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

13 ANSWERS

10580530.trn



G1 O, S, N

Structure attributes must be viewed using STN Express query preparation.

10580530.trn

FILE LAST UPDATED: 5 May 2009 (20090505/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11  
L12            20 L11

=> d cbib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

## 10580530.trn

L12 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2009:25069 Document No. 150:98373 Preparation of piperazinyl derivatives useful as therapeutic modulators of the neuropeptide Y2 receptor.

Dvorak,

Curt A.; Swanson, Devin M.; Wong, Victoria D. (Janssen Pharmaceutica, N. V., Belg.) PCT Int. Appl. WO 2009006185 A1 20090108, 78pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-US68289 20080626. PRIORITY: US 2007-947758P 20070703.

AB The present invention is directed to piperazinyl derivs. useful as inhibitors of the NPY Y2 receptor, pharmaceutical compns. comprising said compds., processes for the preparation of said compds. and the use of said compds. for the treatment and / or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. More specifically, the present invention is directed to N-[4-(4-

(diethylcarbamoylphenylmethyl)piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide (I), N-[4-(4-(ethylcarbamoylphenylmethyl)piperazin-1-yl)-3-fluorophenyl]-2-pyridin-3-ylbenzamide, N-[4-(4-(diethylcarbamoylphenylmethyl)piperazin-1-yl)-3-fluorophenyl]amide, and their enantiomers and pharmaceutically acceptable salts. Synthetic procedures for preparing the compds. of the invention are

exemplified. For example, I was prepared in a multistep synthesis culminating in the reaction of 2-[4-(4-amino-2-fluorophenyl)piperazin-1-yl]-N,N-diethyl-2-phenylacetamide (preparation given) and 2-pyridin-3-ylbenzoic acid.

In neuropeptide Y2 radioligand binding assay for the human Y2 receptor, I had a pK<sub>i</sub> of 8.26.

IT 1094873-26-3P, Biphenyl-2-carboxylic acid N-[4-(4-[(N,N-diethylcarbamoyl)[phenyl]methyl)piperazin-1-yl]-3-

fluorophenyl]amide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazinyl derivs. useful as therapeutic

modulators of neuropeptide Y2 receptor)


RN 1094873-26-3 CAPLUS

CN 1-Piperazineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]-2-fluorophenyl]-N,N-diethyl- $\alpha$ -phenyl- (CA INDEX NAME)

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2008:1483375 Document No. 150:354010 Preparation of piperidine/piperazine derivatives as DGAT inhibitors. Bongartz, Jean-Pierre Andre Marc; Linders, Joannes Theodorus Maria; Meerpoel, Lieven; Van Lommens, Guy Rosalia Eugeen; Coesemans, Erwin; Braeken, Miriele; Buyck, Christophe Franciscus Robert Nestor; Berwaer, Monique Jenny Marie; De Waepenaert, Katharina Antonia Germania J. M.; Roeven, Peter Walter Maria; Davidenko, Petr Vladimirovich (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl.

WO 2008149849 A1 20080121, 128pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GI, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LA, LC, LR, LS, LT, LY, MA, MD, ME, MG, MK, MN, MW, MV, MZ, NA, NG, NJ, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CV, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NC, PI, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-EP57008 20080605. PRIORITY: EP 2007-109866 20070608.

GI




II

AB The title compds. I [A = CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X = OC(O), C(O)C(O), ZC(O), C(O)Z, etc. (Z = (un)substituted alkenediyl, alkenediyil, alkynediyl); R1 = adamantlyl, cycloalkyl, (un)substituted (hetero)aryl; Y = C(O)NRx or NRxC(O) (wherein Rx = H or alkyl; Z2 = (un)substituted alkenediyl, alkenediyil, alkynediyl); R2 = (un)substituted cycloalkyl, Ph, naphthalenyl, etc.; R7 = H, halo, alkyl, hydroxylalkyl], useful as DGAT inhibitors, were prepared and formulated. E.g., a multi-step synthesis of

II, starting from 1,1-dimethylethyl [4-(4-piperidinyl)phenyl]carbamate and 1,3-dichloro-2-isocyanobenzene, was given. Exemplified compds. I were tested for inhibition of DGAT1. For example, II showed pIC<sub>50</sub> of 8.09. The invention further relates to methods for preparing compds. I, pharmaceutical compns. comprising said compds. as well as the use as a medicine of said compds.

L12 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




IT 1094873-25-2P, 4-[4-[(Biphenyl-2-yl)carbonyl]amino]-2-fluorophenyl)piperazine-1-carboxylic acid tert-butyl ester RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of piperazinyl derivs. useful as therapeutic modulators

of neuropeptide Y2 receptor)

RN 1094873-25-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]-2-fluorophenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 1092503-03-6P 1092503-10-0P 1092503-12-2P

1092503-38-2P 1092503-64-4P 1092503-65-5P

1092503-66-6P 1092503-67-7P 1092503-69-9P

1092503-70-2P 1092503-74-6P 1092503-77-9P

1092503-78-0P 1092503-79-1P 1092503-80-4P

1092503-81-5P 1092503-82-6P 1092503-83-7P

1092503-84-8P 1092503-85-9P 1092503-86-0P

1092503-87-1P 1092503-88-2P 1092503-89-3P

1092503-90-6P 1092503-91-7P 1092503-92-8P

1092503-93-9P 1092503-94-0P 1092503-95-1P

1092503-96-2P 1092503-97-3P 1092503-98-4P

1092503-99-5P 1092504-00-1P 1092504-01-2P

1092504-02-3P 1092504-03-4P 1092504-04-5P

1092504-05-6P 1092504-06-7P 1092504-07-8P

1092504-08-9P 1092504-09-0P 1092504-10-3P

1092504-11-4P 1092504-12-5P 1092504-13-6P

1092504-14-7P 1092504-15-8P 1092504-16-9P

1092504-17-0P 1092504-18-1P 1092504-19-2P

1092504-20-5P 1092504-21-6P 1092504-22-7P

1092504-23-8P 1092504-24-9P 1092504-25-0P


1092504-26-1P 1092504-51-2P 1092506-99-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine/piperazine derivs. as DGAT inhibitors)


RN 1092503-08-6 CAPLUS

CN 1-Piperazinecarboxamide, N-(cyclohexylmethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092503-10-0 CAPLUS


CN 1-Piperazinecarboxamide, N-(2-methylphenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092503-12-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(4'-trifluoromethyl)(1,1'-biphenyl)-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-38-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(4'-(1,1-dimethylethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-64-4 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[4-[(4-(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]-N-(2,6-dichlorophenyl)- (CA INDEX NAME)




RN 1092503-65-5 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[4-[(4-(4-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N-(2,6-dichlorophenyl)- (CA INDEX NAME)




L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
RN 1092503-66-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(5-methyl-4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-67-7 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(6-methyl-4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-69-9 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(4'-(1-methylethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-70-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(4'-(1,1-dimethylethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-74-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,6-dichlorophenyl)-4-[4-[(5-methyl-4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-77-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-(1,1-dimethylpropyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-78-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-(phenylmethyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-79-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-(3-phenylpropyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-80-4 CAPLUS  
CN Benzoic acid, 4-[[4-[[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperazinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1092503-81-5 CAPLUS  
CN 1-Piperazinecarboxamide, N-[4-(dimethylamino)phenyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-82-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-methylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 1092503-83-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-ethylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092503-84-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-propylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




## 10580530.trn

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1092503-85-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[2-(1-methylethyl)phenyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)




RN 1092503-86-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-[2-(1,1-dimethylethyl)phenyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)




RN 1092503-87-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[2-(1-methylpropyl)phenyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1092503-88-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-methoxyphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)



RN 1092503-89-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-ethoxyphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)


L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1092503-90-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,6-dimethylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)




RN 1092503-91-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-ethyl-6-methylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)


L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1092503-92-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,6-dimethoxyphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX NAME)




RN 1092503-93-9 CAPLUS  
CN 1-Piperazinecarboxamide, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)-N-(2,6-trimethylphenyl)- (CA INDEX NAME)




10580530.trn

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1092503-94-0 CAPLUS  
CN Benzoic acid, 2-[[4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl-1-piperazinylcarbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 1092503-95-1 CAPLUS  
CN Benzoic acid, 2-[[4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl-1-piperazinylcarbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1092503-96-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-bromophenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1092503-97-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-chlorophenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092503-98-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-fluorophenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1092503-99-5 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-iodophenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-00-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-nitrophenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1092504-01-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-[2-(methylthio)phenyl]-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-02-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-chloro-6-methylphenyl)-4-[4-[(4'-trifluoromethyl)biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-03-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-methyl-6-nitrophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-04-5 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-bromo-4,6-difluorophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-05-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,4,6-tribromophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-06-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-(4-bromo-2,6-difluorophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-07-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,4,6-trichlorophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-08-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-(4-bromo-2,6-dimethylphenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-09-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,3-dimethyl-6-nitrophenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-10-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-chloro-4,6-dimethylphenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-11-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-bromo-4,6-dimethylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-12-5 CAPLUS  
CN 1-Piperazinecarboxamide, N-(3-bromo-2,4,6-trimethylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-13-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2-phenoxyphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-14-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-15-8 CAPLUS  
CN 1-Piperidinecarboxamide,  
N-2-propen-1-yl-4-[(4-((4-(trifluoromethyl)biphenyl)-2-yl)carbonyl)amino]phenyl- (CA INDEX NAME)




RN 1092504-16-9 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-ethylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 1092504-17-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-[2-(1-methylethyl)phenyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-




RN 1092504-18-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-ethyl-6-methylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 1092504-19-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dimethoxyphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

10580530.trn

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN




RN 1092504-20-5 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-N-(2,(4,6-trimethylphenyl)- (CA INDEX NAME)




RN 1092504-21-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-4-[4-[(4'-trifluoromethyl)1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)

(Continued)

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1092504-22-7 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-bromo-4,6-difluorophenyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092504-23-8 CAPLUS  
CN 1-Piperidinecarboxamide, N-(4-bromo-2,6-dimethylphenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX)

112 ANSWER 2 OF 20 CARLIS COPYRIGHT 2009 ACS on STN

(Continued)




RN 1092504-24-9 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,3-dimethyl-6-nitrophenyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 1092504-25-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-chloro-4,6-dimethylphenyl)-4-[4-[(4'-(trifluoromethyl)[1,1'biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)

1-12 ANSWER 2 OF 20 CARLIS COPYRIGHT 2009 ACS on STN


(Continued)




RN 1092504-26-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-bromo-4,6-dimethylphenyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 1092504-51-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-cyclohexyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
RN 1092506-99-4 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2-chloro-6-methylphenyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




L12 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2008:915836 Document No. 149:215973 Use of microsomal triglyceride transfer protein inhibitors for increasing levels of satiety hormones. King, Peter

John; Hrupka, Brian Joel; Borghys, Herman Karel; Berwaer, Monique Jenny Marie; Roeven, Peter Walter Maria (Janssen Pharmaceutica N. V., Belg.).  
PCT Int. Appl. WO 2008090198 A1 20080731, 19pp. DESIGNATED STATES: WI, AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, RW, AI, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2008-EP50814 20080124. PRIORITY: EP 2007-101162

20070125.  
AB The invention discloses the use of inhibitors of microsomal triglyceride transfer protein (MTP), e.g.  
(+)-Phenyl[4-((4'-trifluoromethylbiphenyl-2-carbonyl)amino)phenyl]piperidin-1-ylacetic acid Me ester, for increasing plasma levels of satiety hormones such as GLP-1, PYY and CCK.

IT 403989-79-7 CAPLUS  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Use of MTP inhibitors for increasing levels of satiety hormones)  
RN 403989-79-7 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



L12 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2008:736015 Document No. 149:70465 Use of microsomal triglyceride transfer protein (MTP) inhibitors for the treatment of obesity using low doses and dose-escalation. Gosselin, Jacques; Hickman, Mary Anne; Suerland, Simon Joseph; Wren, Jody Ann (Pfizer Limited, UK). PCT Int. Appl. WO 2008072056 A1 20080619, 34pp. DESIGNATED STATES: W, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LA, LY, MA, MD, MG, MK, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-IB3842 20071203. PRIORITY: US 2006-870010P 20061214.


AB A method of treating a subject suffering from obesity or related eating disorders and/or reducing food consumption comprising administering to the subject an initial amount of an MTP inhibitor effective to ameliorate the obesity or disorder yet low enough to reduce the side effects associated with

administration of the MTP inhibitor, optionally followed by administration of at least one step-wise, escalating dosage of the MTP inhibitor and, optionally, followed by a weight maintenance/management or retraining phase.

IT 403989-79-7, R 256918  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MTP inhibitors for treatment of obesity using low doses and dose-escalation)

RN 403989-79-7 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



L12 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2008:734515 Document No. 149:70464 Method for treatment of obesity or related eating disorders with an microsomal triglyceride transfer protein (MTP) inhibitor in conjunction with an increased-fat diet. Gosselin, Jacques; Hickman, Mary Anne; Wren, Jody Ann (Pfizer Products Inc., USA). PCT Int. Appl. WO 2008072061 A1 20080619, 40pp. DESIGNATED STATES: WI, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LA, LY, MA, MD, MG, MK, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-IB3855 20071203. PRIORITY: US 2006-870018P 20061214.


AB A method for treating a subject suffering from obesity or related eating disorders and/or reducing food consumption comprising administering to the subject a therapeutically effective amount of an MTP inhibitor (e.g. dirofibrate) in conjunction with an increased-fat diet.

IT 403989-79-7, R 256918  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microsomal triglyceride transfer protein inhibitor in conjunction with

increased-fat diet for treatment of obesity or related eating disorder)

RN 403989-79-7 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (+)- (CA INDEX NAME)


Rotation (+).



L12 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2006:388740 Document No. 144:3820140. Ester derivative having MTP inhibitory effects, and pharmaceutical use thereof. Hagiwara, Atsushi; Ikenogami, Taku; Kurihara, Kazunori; Taniguchi, Toshio; Takahashi, Mitsuru; Ida, Akio

(Japan Tobacco Inc., Japan). PCT Int. Appl. WO 2006043510 A1 20060427, 196 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIIXD2. APPLICATION: WO 2005-JP19041 20051017. PRIORITY: JP 2004-303513 20041019; US 2004-621840P 20041025; JP 2005-50469 20050225;

US 2005-658820P 20050304.  
GI




AB Disclosed are an ester compound represented by the general formula I (R1 = halogen, Cl-6 alkyl, alkoxy, etc.; R2 = H, Cl-6 alkyl; R3, R4, R5 = H, alkyl, etc.; R6, R7 = H, Cl-6 alkyl, N-containing hetero ring group, etc; ring A, B, C = C3-14 carbon ring, hetero ring; X = CH2, etc.) or a pharmaceutically acceptable salt thereof, and use of them. The compound or a pharmaceutically acceptable salt thereof is very quickly eliminated from the body when compared with conventional MTP inhibitors, while having excellent MTP inhibitory activity. Consequently, the compound or a pharmaceutically acceptable salt thereof is useful as a drug for preventing or treating hyperlipidemia and the like. For example, 3-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl)biphenyl-2-carbonyl]amino]phenylpropionic acid Ph ester (II) was prepared, and in vitro tested for its inhibitory effect on MTP activity. Also a capsule containing II 30 mg/capsule was formulated.


IT 883241-09-6P 883241-10-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L12 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 883241-55-2 CAPLUS  
CN 4-Piperidinocarboxylic acid, 1-[3-(dimethylamino)carbonyl]-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




L12 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ester derivs. having MTP inhibitory effects, and pharmaceutical use thereof)


RN 883241-09-3 CAPLUS

CN 4-Piperidinocarboxylic acid, 1-[3-(dimethylamino)carbonyl]-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 4-(methoxycarbonyl)phenyl ester (CA INDEX NAME)



RN 883241-10-9 CAPLUS

CN 4-Piperidinocarboxylic acid, 1-[3-(dimethylamino)carbonyl]-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-fluoro-4-(methoxycarbonyl)phenyl ester (CA INDEX NAME)



IT 883241-54-1P 883241-55-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of ester derivs. having MTP inhibitory effects)

RN 883241-54-1 CAPLUS

CN 4-Piperidinocarboxylic acid, 1-[3-(dimethylamino)carbonyl]-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)

(CA INDEX NAME)

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

2005:564639 Document No. 143:780930 Preparation of N-aryl piperidine substituted biphenylcarboxamides as ApoB inhibitors. Meerpael, Lieven; Vellevoorde, Marcel (Janssen Pharmaceutica N. V., Belg.). PCT Int. Appl. WO 2005058824 A2 20050630, 46 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BZ, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIIXD2. APPLICATION: WO 2004-EP53280 20041206.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I (R1 = H, alkyl, halo, etc.; R2 = H, alkyl, halo, etc.; R3 = H, alkyl; R4 = H, alkyl, halo; n = 0-1; X = C and Q is C or X = N and Q is C or X = C and Q is N; W = C, Y = O, NR6; R6 = H, alkyl; m = 0-2; Z = O, NH; R7 = H, (un)substituted alkyl, aryl, etc.; R8 = H, alkyl; R9 = H, alkyl, (un)substituted Ph, etc.) and their pharmaceutically acceptable salts, are prepared and disclosed. Thus, e.g., II was prepared by coupling of 4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylic acid with 1-(4-aminophenyl)-4-piperidine acetic acid Et ester followed by hydrolysis and subsequent coupling with 2-(ethoxycarbonyl)piperidine. The activity of I was evaluated by quantifying the secretion of ApoB using liquid scintillation counting and it was revealed that compds. of the invention possessed pIC50 values in the range of <6 up to 8.22. I should prove useful in the treatment of hyperlipidemia, obesity and type II diabetes. Pharmaceutical compns. comprising I are disclosed.

IT 856000-42-5P 856000-45-8P 856000-47-0P  
856000-50-5P 856000-51-6P 856000-52-7P  
856000-70-9P 856000-71-0P 856000-72-1P  
856000-73-2P 856000-74-3P 856000-75-4P  
856000-76-5P 856000-77-6P 856000-78-7P  
856000-79-8P 856000-80-1P 856000-81-2P  
856000-82-3P 856000-83-4P 856000-85-6P  
856000-86-7P 856000-88-9P 856000-89-0P  
856000-90-3P 856000-91-4P 856000-93-6P  
856000-94-7P 856000-95-8P 856000-96-9P  
856000-97-0P 856000-98-1P 856000-99-2P  
856000-01-9P 856001-02-0P 856001-04-2P  
856001-05-3P 856001-06-4P 856001-07-5P  
856001-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl piperidine substituted biphenylcarboxamides as ApoB inhibitors)


RN 856000-42-5 CAPLUS

CN L-Alanine, N-[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-

10580530.trn

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856000-45-8 CAPLUS

CN L-Valine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-47-0 CAPLUS

CN L-Alanine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 856000-50-5 CAPLUS

CN L-Tryptophan, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-51-6 CAPLUS

CN L-Methionine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856000-52-7 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid,  
 $\beta$ -[[2-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856000-70-9 CAPLUS

CN D-Alanine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 856000-71-0 CAPLUS

CN L-Valine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856000-72-1 CAPLUS


CN D-Valine, N-[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonylamino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-73-2 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[[2-[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]amino]-, ethyl ester, ( $\alpha\text{R}$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-74-3 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[[2-[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]amino]-, ethyl ester, ( $\alpha\text{S}$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-75-4 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[[2-[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]amino]-, methyl ester, ( $\alpha\text{S}$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-76-5 CAPLUS  
CN L-Phenylalanine, N-[[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-77-6 CAPLUS  
CN D-Phenylalanine, N-[[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-78-7 CAPLUS  
CN  $\beta$ -Alanine, N-[[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 856000-79-8 CAPLUS  
CN Butanoic acid, 4-amino-2-[[2-[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester, ( $2\text{S}$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-80-1 CAPLUS  
CN L-Ornithine, N2-[[1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-81-2 CAPLUS  
CN L-Lysine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-82-3 CAPLUS  
CN L-Leucine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-83-4 CAPLUS  
CN L-Tyrosine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-85-6 CAPLUS  
CN Glycine, N-methyl-N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 856000-86-7 CAPLUS  
CN L-Glutamic acid, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-88-9 CAPLUS  
CN L-Aspartic acid, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-89-0 CAPLUS  
CN Glycine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 856000-90-3 CAPLUS  
CN D-Alanine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]carboxyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 856000-91-4 CAPLUS


CN L-Alanine, N-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 856000-93-6 CAPLUS

CN D-Alanine, N-[1-[5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyrimidinyl]-4-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(CA INDEX NAME)

RN 856000-96-9 CAPLUS


CN Glycine, N-[1-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 856000-97-0 CAPLUS  
CN D-Alanine, N-[1-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 856000-98-1 CAPLUS  
CN L-Alanine, N-[1-[5-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 856000-94-7 CAPLUS

CN L-Alanine, N-[1-[5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyrimidinyl]-4-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 856000-95-8 CAPLUS

CN Alanine,  
2-methyl-N-[1-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI)L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
Absolute stereochemistry. Rotation (-).RN 856000-99-2 CAPLUS  
CN L-Alanine, N-[1-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

RN 856000-01-9 CAPLUS  
CN L-Alanine, N-[1-[6-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-3-pyridinyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10580530.trn

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 856001-02-0 CAPLUS  
CN 4-Piperidineacetamide, N-[(1S)-2-(ethylamino)-1-methyl-2-oxoethyl]-1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856001-04-2 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-(ethylamino)-2-oxoethyl ester (CA INDEX NAME)




RN 856001-05-3 CAPLUS  
CN L-Glutamic acid,  
N-[[1-4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 856001-08-6 CAPLUS  
CN  $\beta$ -Alanine, N-[[1-4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 666845-13-2P 666845-14-3P 666845-17-6P  
856001-09-7P 856001-10-0P 856001-11-1P  
856001-12-2P 856001-15-5P 856001-16-6P  
856001-17-7P 856001-27-9P 856001-29-1P  
856001-30-4P 856001-34-8P 856001-35-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of N-aryl piperidine substituted biphenylcarboxamides as ApoB inhibitors)


RN 666845-13-2 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 666845-14-3 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856001-06-4 CAPLUS  
CN L-Tryptophan, N-[[1-4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 856001-07-5 CAPLUS  
CN L-Glutamic acid,  
N-[[1-4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 666845-17-6 CAPLUS  
CN 4-Piperidineacetamide, 1-[5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 856001-09-7 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 856001-10-0 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)


10580530.trn

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 856001-11-1 CAPLUS  
CN 4-Piperidinocarboxylic acid,  
1-[4-[[4'-(trifluoromethyl) [1,1'-biphenyl]-2-  
yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 856001-12-2 CAPLUS  
CN 4-Piperidinocarboxylic acid,  
1-[4-[[4'-(trifluoromethyl) [1,1'-biphenyl]-2-  
yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 856001-15-5 CAPLUS  
CN 4-Piperidinocarboxylic acid,  
1-[5-[[4'-(trifluoromethyl) [1,1'-biphenyl]-2-


L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
y1]carbonyl]amino]-2-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 856001-16-6 CAPLUS  
CN 4-Piperidinocarboxylic acid,  
1-[5-[[4'-(trifluoromethyl) [1,1'-biphenyl]-2-  
yl]carbonyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)




RN 856001-17-7 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]- (CA INDEX NAME)




RN 856001-27-9 CAPLUS  
CN 4-Piperidineacetic acid, 1-[6-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]-3-pyridinyl]-, ethyl ester (CA INDEX  
NAME)

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 856001-29-1 CAPLUS  
CN 4-Piperidineacetic acid, 1-[6-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]-3-pyridinyl]- (CA INDEX NAME)




RN 856001-30-4 CAPLUS  
CN L-Alanine, N-[[1-4-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856001-34-8 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-oxo-2-(phenylmethoxy)ethyl  
ester (CA INDEX NAME)

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 856001-35-9 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[6-methyl-4'-(trifluoromethyl) [1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl]-, carboxymethyl ester (CA INDEX  
NAME)



10580530.trn

L12 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2004:510477 Document No. 141:651080 Pharmaceutical compositions containing biphenylcarboxamide derivatives having ApoB secretion-inhibiting and hypolipemic effects. Yuzunaka, Masayuki; Kusama, Mari; Kamatani, Hiroshi; Tanaka, Keiko; Igarashi, Shigeki (Tanabe Seiyaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2004175739 A 20040624, 59 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2002-345077 20021128.

GI




AB Claimed are compns. containing the title compds. I [R1 = lower (halo)alkyl, CONR5R6 (R5, R6 = alkyl, aryl-lower alkyl), II (n = 0-3); R2 = H, CO2H, lower alkoxy carbonyl, lower alkoxy, lower alkoxy-lower alkoxy, morpholinyl-lower alkoxy, cyano, carbamoyl, mono- or di-(lower alkyl)carbamoyl; Y = CH, N; R3 = III (m = 0-3; R7 = organic group), (CH2)pNR8 (p = 1-6; R8 = organic group; if R2 = H, then R8 ≠ SO2Ph, CO2Me), CONH(CH2)qR9 [q = 1-6; R9 = (un)substituted heterocyclyl]; R4 = H, halo] or their pharmacol. acceptable salts. The compns. are useful for prevention and treatment of hyperlipidemia, atherosclerosis, apoplexy, thrombosis, diabetes, obesity, etc.  
 1-[4-[2-(4-Trifluoromethylphenyl)benzoylamino]phenyl]-3-methoxycarbonylamino pyrrolidine (IV, preparation given) inhibited ApoB secretion by HepG2 cells at IC50 1.7 nM. IV also decreased plasma triglycerides in rats fed olive oil.

IT 478034-31-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of biphenylcarboxamide derivs. as ApoB secretion inhibitors and hypolipemics)

RN 478034-34-3    CAPLUS  
 CN Carbamic acid, [1-[4-[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-y]carbonylamino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 hypolipemics)  
 RN 478034-31-0    CAPLUS  
 CN Carbamic acid, [1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y]carbonylamino]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 478034-34-3P 478034-35-4P 478034-36-5P  
 478034-37-6P 478034-38-7P 478034-39-8P  
 478034-81-0P 478034-82-1P 478034-83-2P  
 478034-84-3P 478034-85-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of biphenylcarboxamide derivs. as ApoB secretion inhibitors and hypolipemics)

RN 478034-34-3    CAPLUS  
 CN Carbamic acid, [1-[4-[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-y]carbonylamino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




L12 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 478034-37-6    CAPLUS  
 CN Carbamic acid, [1-[4-[[6-(dimethylamino)carbonyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-y]carbonylamino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-38-7    CAPLUS  
 CN Carbamic acid, [1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y]carbonylamino]-2-pyridinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-39-8 CAPLUS  
CN Carbamic acid, [1-[4-[[[4'-(dimethylamino)carbonyl][1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-81-0 CAPLUS  
CN Carbamic acid, [1-[4-[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 478034-82-1 CAPLUS  
CN Carbamic acid, [1-[4-[[6-[2-(4-morpholinyl)ethoxy]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 478034-83-2 CAPLUS  
CN Carbamic acid, [1-[4-[[6-(2-methoxyethoxy)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI)



RN 478034-84-3 CAPLUS  
CN Carbamic acid, [1-[4-[[6-[(dimethylamino)carbonyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 478034-85-4 CAPLUS  
CN Carbamic acid, [1-[5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2004:182706 Document No. 140:2357390 preparation of N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein B secretion. Meerpoel, Lieven; Backx, Leo Jacobus Jozef; Koevens, Peter Walter Maria (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2004017969 A1 20040304, 34 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXDB. APPLICATION: WO 2003-EP68694 20030805. PRIORITY: EP 2002-78309 20020812.

GI



AB N-[piperidinyl or heteroaryl]biphenylcarboxamides of formula (I), N-oxides, pharmaceutically acceptable acid addition salts, or stereoisomeric forms thereof, (wherein R1, R2 = H, Cl-4 alkyl, halo, polyhalo-Cl-4 alkyl; R3 = H, Cl-4 alkyl; R4 = H, Cl-4 alkyl, halo; n = 0, 1; X1 and X2 are either both carbon, or when one of X1 or X2 is nitrogen, than the other X1 or X2 is carbon; X3 is carbon, or nitrogen provided that only one of X1 or X2 is nitrogen; Y = O, NR6 (wherein R6 = H, Cl-4 alkyl); R5 = H, (a) Cl-6alkyl optionally substituted with Cl-4alkyloxy, cyano, polyhalo-Cl-4 alkyl, or aryl, (B) C2-6 alkenyl optionally substituted with aryl, (c) C3-6 alkynyl optionally substituted with aryl, (c) aryl or heteroaryl; aryl = (un)substituted phenyl; heteroaryl = each (un)substituted pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolyl, furanyl, or thiienyl) are prepared. Also disclosed are pharmaceutical compds. comprising said compds. I as well as the use of said compds. I as a medicine for the treatment of hyperlipidemia, obesity, and type II diabetes. The compds. I have apolipoprotein B inhibiting activity and concomitant lipid lowering activity. Thus,


L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 6-methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (prepn. given) was treated with SOCl<sub>2</sub> in CH<sub>2</sub>C<sub>12</sub> in the presence of a few drops of DMF at 40° and the resulting acid chloride was condensed with [1-[4-(aminophenyl)piperidin-4-yl]acetic acid Et ester in CH<sub>2</sub>C<sub>12</sub> in the presence of Et<sub>3</sub>N on room temp. for 90 min to give [1-[4-(6-methyl-4'-trifluoromethylbiphenyl-2-carboxyphenyl)amino]phenyl]piperidin-4-yl]acetic acid Et ester (II). II and N-[4-[4-(benzylcarbamoyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide showed -logIC<sub>50</sub> of 7.947 and 8.448, resp., for inhibiting the secretion of apolipoprotein B from HepG2 cells.  
 IT 666845-04-1P, N-[4-[4-(Benzylcarbamoyl)piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-05-2P,  
 N-[4-[4-(Benzylcarbamoyl)methyl]piperidin-1-yl]phenyl]-4'-tert-butyl-1,1'-biphenyl-2-carboxamide 666845-06-3P,  
 N-[4-[4-(Benzylcarbamoyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-07-4P,  
 N-[4-[4-(Ethylcarbamoyl)piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-08-5P,  
 N-[4-[4-(Ethylcarbamoyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-09-6P,  
 N-[4-[4-(Ethylcarbamoyl)piperidin-1-yl]phenyl]-4'-tert-butyl-1,1'-biphenyl-2-carboxamide 666845-10-9P,  
 N-[4-[4-(Ethylcarbamoyl)methyl]piperidin-1-yl]phenyl]-4'-tert-butyl-1,1'-biphenyl-2-carboxamide 666845-11-0P,  
 N-[4-[4-(Benzylcarbamoyl)piperidin-1-yl]phenyl]-4'-tert-butyl-1,1'-biphenyl-2-carboxamide 666845-12-1P,  
 N-[4-[4-(Methoxycarbonyl)piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-13-2P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-6-methyl-1,1'-biphenyl-2-carboxamide 666845-14-3P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-15-4P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-5-methyl-1,1'-biphenyl-2-carboxamide 666845-16-5P,  
 N-[6-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]pyridin-3-yl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-17-6P,  
 N-[6-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]pyridin-3-yl]-4'-trifluoromethyl-6-methyl-1,1'-biphenyl-2-carboxamide 666845-18-7P,  
 N-[6-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]pyridin-3-yl]-4'-trifluoromethyl-5-methyl-1,1'-biphenyl-2-carboxamide 666845-19-8P,  
 N-[2-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]pyrimidin-5-yl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-20-1P,  
 N-[2-[4-(Carboxymethyl)piperidin-1-yl]pyrimidin-5-yl]-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide 666845-21-2P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-

L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 6-methyl-1,1'-biphenyl-2-carboxamide hydrochloride 666845-22-3P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-6-methyl-1,1'-biphenyl-2-carboxamide methanesulfonate 666845-23-4P,  
 N-[4-[4-(Ethoxycarbonyl)methyl]piperidin-1-yl]phenyl]-4'-trifluoromethyl-6-methyl-1,1'-biphenyl-2-carboxamide maleate  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Prepn. of N-[piperidinyl(hetero)aryl]biphenylcarboxamides as inhibitors of apolipoprotein B secretion and lipid lowering agents for treatment of hyperlipidemia, obesity, and type II diabetes)  
 RN 666845-04-1 CAPLUS  
 CN 4-Piperidinecarboxamide, N-(phenylmethyl)-1-[4-[[4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


RN 666845-05-2 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)

RN 666845-06-3 CAPLUS  
 CN 4-Piperidineacetamide, N-(phenylmethyl)-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 666845-07-4 CAPLUS  
 CN 4-Piperidinecarboxamide, N-ethyl-1-[4-[[4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 666845-08-5 CAPLUS  
 CN 4-Piperidineacetamide, N-ethyl-1-[4-[[4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

10580530.trn



L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 666845-09-6 CAPLUS  
CN 4-Piperidinocarboxamide, 1-[4-[(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-N-ethyl- (CA INDEX NAME)



RN 666845-10-9 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N-ethyl- (CA INDEX NAME)




RN 666845-11-0 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[4-[(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 666845-12-1 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-


L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 666845-13-2 CAPLUS  
CN 4-Piperideineacetic acid, 1-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 666845-14-3 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]aminophenyl]-, ethyl ester (CA INDEX NAME)




RN 666845-15-4 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)


L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 666845-16-5 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]2-pyridinyl]-, ethyl ester (CA INDEX NAME)




FRN 666845-17-6 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl-, ethyl ester (CA INDEX NAME)




RN 666845-18-7 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-, ethyl ester (CA INDEX NAME)




RN 666845-19-8 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 666845-20-1 CAPLUS  
CN 4-Piperidineacetic acid, 1-[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)



RN 666845-21-2 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 666845-22-3 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 666845-13-2

CMF C30 H31 F3 N2 O3



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 666845-23-4 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 666845-13-2  
CMF C30 H31 F3 N2 O3



CM 2


CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



L12 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2003-454287 Document No. 139;365480 Preparation of N-(4-piperazinophenyl)benzamides as apoB-100 and/or MTP inhibitor. Daugan, Alain Claude-Marie; Dodic, Nerina (Glaxo Group Limited, UK). PCT Int Appl. WO 2003048121 A1 20030612, 45 pp. DESIGNATED STATES: W, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE', ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR', KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ', OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ', UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; PNT: AJ, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP13592 200201202. PRIORITY: GB 2001-29015 20011204.


GI




AB The title compds. [I]; R1 = iso-Pr, CF3; R2 = iso-Pr, Cl, F, CF3; R3 = alkyl, alkenyl, cycloalkyl, alkylsulfonyl, acyl, CH2R4; R4 = (un)substituted Ph, 5-6 membered heteroarom. group, cycloalkyl, etc., useful in therapy, particularly in the treatment or prophylaxis of conditions ameliorated by an apoB-100 and/or MTP inhibitor. Thus, reacting 4',6-diisopropyl-biphenyl-2-carboxylic acid (4-piperazin-1-ylphenyl)amide (multi-step preparation given) with 1H-pyrrole-2-carbaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2 afforded I [R1, R2= iso-Pr; R3 = 1H-pyrrol-2-ylmethyl]. All of the exemplified compds. I had an IC50 of 0.2 mM or below in vitro MTP assay.

IT 540764-90-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of N-(4-piperazinophenyl) benzamides as apo-100 and/or MTP inhibitor)


RN 540764-90-7 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




IT 540764-86-1P 540764-87-2P 540765-04-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);  
 (preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor)  
 RN 540764-86-1 CAPLUS  
 CN 1-Piperazineacetamide, 4-[4-[[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 540764-87-2 CAPLUS  
 CN 1-Piperazineacetamide,  
 4-[4-[[6-(1-methylethyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 540765-04-6 CAPLUS  
 CN 1-Piperazineacetic acid,  
 4-[4-[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



IT 378231-12-0P, 4-[4-[(4',6-Diisopropyl-biphenyl-2-carbonyl)amino]phenyl]piperazine-1-carboxylic acid tert-butyl ester  
 378231-13-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor)  
 RN 378231-12-0 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 378231-13-1 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-(1-methylethyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L12 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2003-454115 Document No. 139:365470 Preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor. Daugan, Alain Claude-Marie; Dodic, Nerina (Glaxo Group Limited, UK). PCT Int. Appl. WO 2003047575 A1 20030612, 32 pp. DESIGNATED STATES: WI, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LY, LR, LS, LT, LV, MA, MD, MG, MN, MW, MX, MY, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, US, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CT, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP13591 20021202. PRIORITY: GB 2001-29013 20011204.

GI




AB The title compds. [I; R1 = alkyl, alkenyl, alkylsulfonyl, acyl, CH2R4; R2 = iso-Pr, CF3; R3 = Me, OMe; R4 = 5-6 membered heteroarom. group selected from thiienyl, thiazolyl and furanyl, etc.], useful in therapy, particularly in the treatment or prophylaxis of conditions ameliorated by an apoB-100 and/or MTP inhibitor, were prepared. Thus, N-alkylation of 4'-Isopropyl-6-methoxybiphenyl-2-carboxylic acid (4-piperazin-1-ylphenyl)amide (multi-step preparation given) with 1-bromopropane afforded I [R1 = Pr; R2 = iso-Pr; R3 = OMe]. The compds.


I had an IC50 of 0.8 nM or below in *in vitro* human MTP assay.  
 IT 273727-32-5P 273727-33-6P 273727-34-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor)  
 RN 273727-32-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 273727-33-6 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-34-7 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methyl-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2002:946251 Document No. 138:247220 Preparation of biphenylcarboxamides as apolipoprotein B secretion inhibitors and hypolipemics. Annaka, Masayuki; Kusama, Mari; Kamaya, Hiroshi; Tanaka, Keiko; Igarashi, Shigeaki (Tanabe Seiyaku Co., Ltd., Japan). PCT Int. Appl. WO 2002098839 A1 20021122, 88 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; PW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GR, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2.  
 APPLICATION: WO 2002-JP5358 20020531. PRIORITY: JP 2001-165989 20010601.

GI




AB The title compds. I [R1 is optionally halogenated lower alkyl or the like; R2 is hydrogen, carboxyl, lower alkoxy carbonyl, lower alkoxy, or the like; Y is CH or N; R3 is a group represented by the general formula  $(CH_2)_pNHR_8$  or the like; p is an integer (1 to 6); R8 is organic moiety; and R4 is hydrogen or halogeno], useful as apolipoprotein B secretion inhibitors and hypolipemics (no data), are prepared. Processes for preparing I are disclosed. For example, 1-(4-(2-(4-trifluoromethylphenyl)benzoylamino)phenyl)-3-(2-pyrimidinyl)aminopyrrolidine was prepared.


IT 478034-31-0P 478034-32-1P  
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of biphenylcarboxamides as apolipoprotein B secretion inhibitors and hypolipemics)

RN 478034-31-0 CAPLUS  
 CN Carbamic acid, [1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 478034-32-1 CAPLUS  
 [1,1'-Biphenyl]-2-carboxylic acid, 6-[[[4-[[3-[(1,1-dimethylethoxy)carbonyl]amino]-1-pyrrolidinyl]phenyl]amino]carbonyl]-4'-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



IT 478034-34-3P 478034-35-4P 478034-36-5P  
 478034-37-6P 478034-38-7P 478034-39-8P  
 478034-80-9P 478034-81-0P 478034-82-1P  
 478034-83-2P 478034-84-3P 478034-85-4P  
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN


L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of biphenylcarboxamides as apolipoprotein B secretion inhibitors and hypolipemics)

RN 478034-34-3 CAPLUS  
 CN Carbamic acid, [1-[4-[[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-35-4 CAPLUS  
 CN Carbamic acid, [1-[4-[[[6-[2-(4-morpholinyl)ethoxy]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 478034-36-5 CAPLUS  
 CN Carbamic acid, [1-[4-[[[6-(2-methoxyethoxy)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-37-6 CAPLUS  
 CN Carbamic acid, [1-[4-[[[6-[(dimethylamino)carbonyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

## 10580530.trn


L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 478034-38-7 CAPLUS

CN Carbamic acid, [1-[5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 478034-39-8 CAPLUS

CN Carbamic acid, [1-[4-[[4'-(dimethylamino)carbonyl][1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 478034-80-9 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 6-[[[4-[3-[(methoxycarbonyl)amino]-1-pyrrolidinyl]phenyl]amino]carbonyl]-4'-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 478034-81-0 CAPLUS

CN Carbamic acid, [1-[4-[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 478034-82-1 CAPLUS


CN Carbamic acid, [1-[4-[[6-[2-(4-morpholinyl)ethoxy]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 478034-84-3 CAPLUS

CN Carbamic acid, [1-[4-[[6-[(dimethylamino)carbonyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 478034-83-2 CAPLUS

CN Carbamic acid, [1-[4-[[6-(2-methoxyethoxy)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 478034-85-4 CAPLUS

CN Carbamic acid, [1-[5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2002-814118 Document No. 137:3254320 Preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor. Daugan, Alain Claude-Marie (Glaxo Group Limited, UK). PCT Int. Appl. WO 2002083658 A1 20021024, 25 pp., DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; BW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP4061 20020411. PRIORITY: GB 2001-9287 20010412.

GI



AB The title compds. [I; R1 = CF<sub>3</sub>, alkyl; R2 = halo, alkyl, alkoxy; R3 = alkyl, alkenyl], useful in therapy, particularly in the treatment or prophylaxis of conditions ameliorated by an apoB-100 and/or MTP inhibitor,

were prepared Thus, N-alkylating I [R1 = CF<sub>3</sub>; R2 = Me; R3 = H] with allyl bromide in acetone containing Cs<sub>2</sub>CO<sub>3</sub> afforded I [R1 = CF<sub>3</sub>; R2 = Me; R3 = allyl] which showed IC<sub>50</sub> of 0.1 nM in MTP assay.

IT 473475-02-4P 473475-03-5P 473475-04-6P


473475-05-7P 473475-06-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(4-piperazinophenyl) benzamides as apoB-100 and/or MTP inhibitor)


RN 473475-02-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473475-03-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 473475-04-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 473475-05-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473475-06-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[4'-(1,1-dimethylethyl)-5-methyl[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 473475-05-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2002:793613 Document No. 137:3109340 Preparation of piperidinyl-,  
 piperazinylcarboxamides as lipid lowering agents. Meerpoel, Lieven;  
 Vieillevooye, Marcel (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl.  
 WO 200201460 A1 20021017, 64 pp. DESIGNATED STATES: W, AE, AG, AL, AM,  
 AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM,  
 DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
 KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NO, NZ, OM, PB, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,  
 RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI,  
 FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.  
 (English). CODEN: PIXKD2. APPLICATION: WO 2002-EP3491 20020327.  
 PRIORITY: EP 2001-201270 20010406.

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [r,s,q = 1-3; p = 0-1; R1 = H, alkyl, alkyloxy, halo, hydroxy, mercapto, cyano, nitro, etc.; R2 = H, alkyl, alkyloxy, halo, CF3; R3 = H, alkyl; R4 = alkyl, alkyloxy, halo, CF3; Z = e.g., -X1(R5)-(CH2)n-X2(R6); n = 2-4; R5-6 = H, alkyl, aryl; X1-2 = CH, N, sp<sup>2</sup> hybridized carbon, etc.; A = bond, alkanediyl, etc.; B = e.g., R8-COO-alkanediyl-Y; Y = O, amino, etc.; R8 = alk(en/y)nyl, etc.] were prepared. For instance, N-(4-(1-piperazinyl)phenyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (preparation given) was reacted with α-chlorobenzenoacetic acid 2-methoxy-2-oxoethyl ester (preparation given, DMF, Na2CO3) to afford, after purification, II, m.p. 106°. II inhibited microsomal triglyceride transfer protein (MTP) activity with pIC50 = 6.591. I are useful for the treatment of hyperlipidemia, obesity and type II diabetes.

IT 1106197-48-1 1106197-49-2  
 1106197-50-5 1106197-51-6 1106197-52-7  
 1106197-53-8 1106197-54-9 1106197-55-0  
 1106197-56-1 1106197-57-2 1106197-58-3  
 1106197-59-4 1106197-60-7 1106197-61-8  
 1106197-62-9 1106197-63-0 1106197-64-1  
 1106197-65-2 1106197-66-3 1106197-67-4  
 RL: PRPH (Prophetic)  
 (Preparation of piperidinyl-, piperazinylcarboxamides as lipid lowering agents)


RN 1106197-47-0 CAPLUS  
 CN β-Alanine, N-[2-phenyl-2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1106197-48-1 CAPLUS


CN Butanoic acid, 4-[(2-phenyl-2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl)acetyl]amino-, methyl ester (CA INDEX NAME)




RN 1106197-49-2 CAPLUS

CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-ethoxy-1,1-dimethyl-2-oxoethyl ester (CA INDEX NAME)


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1106197-50-5 CAPLUS  
 CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-(ethoxycarbonyl)propyl ester (CA INDEX NAME)




RN 1106197-51-6 CAPLUS  
 CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-(ethoxycarbonyl)-2-methylpropyl ester (CA INDEX NAME)




L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 1106197-52-7 CAPLUS  
 CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-(ethoxycarbonyl)butyl ester (CA INDEX NAME)



RN 1106197-53-8 CAPLUS  
 CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-(ethoxycarbonyl)pentyl ester (CA INDEX NAME)




RN 1106197-54-9 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED




10580530.trn

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1106197-55-0 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-cyclohexyl-2-methoxy-2-oxoethyl ester (CA INDEX NAME)




RN 1106197-56-1 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED




RN 1106197-57-2 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-cyclopentyl-2-methoxy-2-oxoethyl ester (CA INDEX NAME)




L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1106197-61-8 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-methoxy-2-oxo-1-phenylethyl ester (CA INDEX NAME)




RN 1106197-62-9 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)




RN 1106197-63-0 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-phenoxyethyl ester (CA INDEX NAME)


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1106197-58-3 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-(4-morpholinyl)ethyl ester (CA INDEX NAME)




RN 1106197-59-4 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)ethyl ester (CA INDEX NAME)




RN 1106197-60-7 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2,2-diethoxyethyl ester (CA INDEX)


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1106197-64-1 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl ester (CA INDEX NAME)




RN 1106197-65-2 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-(diethylamino)-2-oxoethyl ester (CA INDEX NAME)




RN 1106197-66-3 CAPLUS

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-methoxy-1,1-dimethyl-2-oxoethyl ester (CA INDEX NAME)



RN 1106197-67-4 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-ethoxy-1-methyl-2-oxoethyl ester (CA INDEX NAME)




IT 471245-06-4P 471245-09-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of amidomethylpiperidinyl/piperazinyl-aryl-carboxamides  
as lipid lowering agents)  
RN 471245-06-4 CAPLUS  
CN Glycine, N-[(1-[4-[(4'-1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino)phenyl]-4-piperidinyl]phenylacetetyl-, methyl ester, compd. with 2-propanol (1:1) (9CI) (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


CM 1

CRN 471245-05-3  
CMF C39 H43 N3 O4




CM 2

CRN 67-63-0  
CMF C3 H8 O



RN 471245-09-7 CAPLUS  
CN Glycine, N-[phenyl[1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl- (9CI) (CA INDEX NAME)




L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 471244-75-4P, 4-[2-[(4-[2-(2-Hydroxyethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-76-5P,  
4-[2-[(4-[2-(2-Aminoethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-76-5P,  
4-[2-[(4-[2-(2-Cyanoethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-77-7P,  
4-[2-[(4-[2-(2-Hydroxyethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-78-7P,  
4-[2-[(4-[2-(2-Hydroxyethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-79-8P, 4-[2-[(4-[2-(2-Aminoethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-80-1P,  
4-[2-[(4-[2-(2-Methoxyethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-81-2P, 4-[2-[(4-[2-(2-Methoxyethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-82-3P,  
4-[2-[(4-[2-(2-Dimethylamino)ethylamino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-83-0P, 4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-84-7P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-85-4P, 4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-86-7P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-87-3P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-88-0P, 4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-89-7P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-90-4P, 4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-91-4P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-92-1P, 471244-93-9P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-94-7P, 471244-95-9P,  
4-[2-[(4-[2-(2-(Methoxycarbonyl)methyl)amino)-2-oxo-1-phenylethyl]piperazinyl)phenyl]amino]carbonylphenyl]-1-trifluoromethylbenzene, 471244-96-9P, 471244-97-0P, 471244-99-2P, 471245-01-9P,  
471245-03-1P, 471245-11-1P, 471245-12-2P, 471245-15-5P, 471245-18-8P, 471245-19-9P, 471245-21-3P, 471245-23-5P, 471245-25-7P, 471245-28-0P, 471245-29-1P, 471245-30-4P, 471245-31-5P, 471245-32-6P, 471245-33-7P, 471245-34-8P, 471245-35-9P, 471245-36-0P, 471245-37-1P, 471245-38-2P, 471245-39-3P, 471245-40-6P, 471245-41-7P, 471245-42-8P, 471245-43-9P, 471245-44-0P, 471245-45-1P, 471245-46-2P, 471245-47-3P, 471245-48-4P, 471245-49-5P, 471245-50-8P, 471245-51-9P, 471245-52-0P, 471245-53-1P, 471245-54-2P, 471245-55-3P, 471245-56-4P, 471245-57-5P, 471245-58-6P, 471245-59-7P, 471245-60-0P, 471245-61-1P, 471245-62-2P, 471245-63-3P, 471245-64-4P, 471245-65-5P, 471245-66-6P, 471245-67-7P, 471245-68-8P, 471245-69-9P, 471245-70-2P, 471245-71-3P, 471245-72-4P, 471245-73-5P, 471245-74-6P, 471245-75-7P, 471245-76-8P, 471245-77-9P, 471245-78-0P, 471245-79-1P, 471245-80-4P, 471245-81-5P, 471245-82-6P, 471245-83-7P, 471245-84-8P


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

471245-85-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(as lipid lowering agents)

471245-85-9P CAPLUS  
1-Piperazineacetamide, N-(2-hydroxyethyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



471244-76-5 CAPLUS  
1-Piperazineacetamide, N-(2-aminoethyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




471244-77-6 CAPLUS  
1-Piperazineacetamide, N-(2-cyanoethyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


10580530.trn

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471244-78-7 CAPLUS  
CN 1-Piperidineacetamide, N-(2-hydroxyethyl)- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 471244-79-8 CAPLUS  
CN 1-Piperidineacetamide, N-(2-aminoethyl)- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 471244-80-1 CAPLUS  
CN 1-Piperidineacetamide, N-(2-methoxyethyl)- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 471244-81-2 CAPLUS  
CN 1-Piperidineacetamide, N-(2,2-dimethoxyethyl)- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 471244-82-3 CAPLUS  
CN 1-Piperidineacetamide, N-[2-(dimethylamino)ethyl]- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471244-86-7 CAPLUS  
CN Glycine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 471244-87-8 CAPLUS  
CN Glycine, N-[4-[4-[[1,1'-biphenyl]-2-ylcarbonyl]amino]phenyl]-1-piperazinyl]phenylacetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 471244-89-0 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-methoxy-2-oxoethyl ester (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 471244-91-4 CAPLUS  
CN Glycine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 471244-94-7 CAPLUS  
CN 1-Piperazineacetic acid,  
4-[4-[[1,1'-biphenyl]-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, 2-methoxy-2-oxoethyl ester compd. with 2-propanol, hydrochloride (1:1:2) (CA INDEX NAME)

CM 1

CRN 471244-93-6  
CMF C34 H33 N3 O5



## 10580530.trn


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)


CM 2

CRN 67-63-0  
CMF C3 H8 O

RN 471244-96-9 CAPLUS  
CN Glycine, N-[4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-1-piperidinylphenylacetyl-, methyl ester (9CI) (CA INDEX NAME)




RN 471244-97-0 CAPLUS  
CN Glycine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylacetyl-, methyl ester (9CI) (CA INDEX NAME)




RN 471244-99-2 CAPLUS  
CN Glycine, N-[1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-4-piperidinylphenylacetyl-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-01-9 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-methoxy-2-oxoethyl ester (CA INDEX NAME)




RN 471245-03-1 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[1,1'-biphenyl]-2-ylcarbonyl]amino]phenyl- $\alpha$ -phenyl-, 2-methoxy-2-oxoethyl ester (CA INDEX NAME)




RN 471245-11-1 CAPLUS  
CN 4-Piperidineacetamide, N-[3-(dimethylamino)propyl]-1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-N-[ethylamino]carbonyl- $\alpha$ -phenyl- (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 471245-12-2 CAPLUS  
CN Glycine, N-[1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylphenylacetyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 471245-15-5 CAPLUS  
CN L-Leucine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylacetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-18-8 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[2-phenyl-2-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinylacetyl-, methyl ester (CA INDEX NAME)




RN 471245-19-9 CAPLUS  
CN L-Tyrosine, N-[phenyl[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinylacetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-21-3 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-23-5 CAPLUS  
CN L-Valine, 3-methyl-N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-25-7 CAPLUS  
CN L-Alanine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-28-0 CAPLUS  
CN L-Methionine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-29-1 CAPLUS  
CN L-Glutamic acid, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471245-30-4 CAPLUS  
CN L-Glutamic acid, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, 5-(1,1-dimethylethyl) 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 471245-31-5 CAPLUS  
CN L-Aspartic acid, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-32-6 CAPLUS  
CN L-Aspartic acid, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-33-7 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[(2-phenyl-2-[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl)acetyl]amino]-, methyl ester (CA INDEX NAME)



RN 471245-34-8 CAPLUS


CN Alanine, 2-methyl-N-[phenyl[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 471245-35-9 CAPLUS


CN L-Histidine, N-[phenyl[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-1-(triphenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-36-0 CAPLUS

CN Glycine, N-methyl-N-[phenyl[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 471245-37-1 CAPLUS


CN Cyclohexanecarboxylic acid, 1-[(2-phenyl-2-[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperazinyl)acetyl]amino]-, methyl ester (CA INDEX NAME)



RN 471245-38-2 CAPLUS

CN L-Aspartic acid, N-[phenyl[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471245-39-3 CAPLUS

CN 1H-Indole-3-propanoic acid,  $\alpha$ -[(2-phenyl-2-[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl)acetyl]amino]-, methyl ester, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 471245-40-6 CAPLUS


CN L-Aspartic acid, N-[phenyl[4-[4-[[4'- (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-, 4-(1,1-dimethylethyl)-1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-41-7 CAPLUS

CN Alanine,  
2-methyl-N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 471245-42-8 CAPLUS

CN L-Histidine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-1-(triphenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-45-1 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-, 2-(4-morpholinyl)ethyl ester (CA INDEX NAME)




RN 471245-46-2 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (CA INDEX NAME)





RN 471245-43-9 CAPLUS

CN Glycine,  
N-methyl-N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 471245-44-0 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-, 1H-benzimidazol-2-ylmethyl ester (CA INDEX NAME)




RN 471245-47-3 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-, 2-(acetamido)ethyl ester (CA INDEX NAME)




RN 471245-48-4 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)




RN 471245-49-5 CAPLUS


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-(phenylamino)ethyl ester (CA INDEX NAME)



RN 471245-50-8 CAPLUS  
 CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2,2-dimethoxyethyl ester (CA INDEX NAME)




RN 471245-51-9 CAPLUS  
 CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-methoxy-2-oxo-1-phenylethyl ester (CA INDEX NAME)




RN 471245-52-0 CAPLUS  
 CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-

PAGE 1-A

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 biphenyl]-2-yl]carbonyl]amino]phenyl-, tetrahydro-3-furanyl ester (CA INDEX NAME)



PAGE 2-A




RN 471245-53-1 CAPLUS  
 CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 471245-54-2 CAPLUS  
 CN L-Leucine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-55-3 CAPLUS  
 CN Benzenearctic acid,  $\alpha$ -methyl- $\alpha$ -[[2-phenyl-2-[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]amino-, methyl ester, (CA INDEX NAME)




L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 471245-56-4 CAPLUS  
 CN L-Tyrosine, N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-57-5 CAPLUS  
 CN Benzenearctic acid,  $\alpha$ -[[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl]amino-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-58-6 CAPLUS  
 CN L-Valine, 3-methyl-N-[phenyl[4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-1-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10580530.trn

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-59-7 CAPLUS

CN L-Alanine, N-[phenyl[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-60-0 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[2-phenyl-2-[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (CA INDEX NAME)


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 471245-63-3 CAPLUS

CN 1-Piperidineacetic acid, alpha-phenyl-4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-, 2-amino-2-oxoethyl ester (CA INDEX NAME)



RN 471245-64-4 CAPLUS

CN 4-Piperidineacetic acid, alpha-phenyl-1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-, 1H-benzimidazol-2-ylmethyl ester (CA INDEX NAME)




RN 471245-65-5 CAPLUS

CN L-Phenylalanine, N-[phenyl[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-61-1 CAPLUS

CN L-Glutamic acid, N-[phenyl[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-62-2 CAPLUS


CN 4-Piperidineacetic acid, alpha-phenyl-1-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
y1]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471245-66-6 CAPLUS

CN L-Serine, N-[phenyl[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 471245-67-7 CAPLUS

CN L-Cysteine, S-(phenylmethyl)-N-[phenyl[4-[4-((trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenyl]-1-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-68-8 CAPLUS  
CN Butanoic acid,  
4-[(2-phenoxy-2-(4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino)phenyl]-1-piperazinyl]acetyl]amino-, methyl ester (9CI) (CA INDEX NAME)




RN 471245-69-9 CAPLUS  
CN L-Alanine, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-70-2 CAPLUS  
CN L-Methionine, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-71-3 CAPLUS  
CN L-Glutamic acid, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-72-4 CAPLUS  
CN L-Tryptophan, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-73-5 CAPLUS  
CN L-Aspartic acid, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471245-74-6 CAPLUS  
CN Alanine,  
2-methyl-N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 471245-75-7 CAPLUS  
CN L-Histidine, N-[phenyl[1-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-(1-triphenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

## 10580530.trn


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 471245-76-8 CAPLUS

CN Glycine,  
N-methyl-N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)




RN 471245-77-9 CAPLUS

CN L-Phenylalanine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-78-0 CAPLUS

CN L-Tyrosine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471245-79-1 CAPLUS

CN L-Alanine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 471245-80-4 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, Z-hydroxyethyl ester (CA INDEX NAME)




RN 471245-81-5 CAPLUS

CN L-Histidine, N-[phenyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-82-6 CAPLUS

CN Glycine, N-[1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]phenylacetyl-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 471245-83-7 CAPLUS


CN Glycine, N-[1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]phenylacetyl-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

10580530.trn

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-84-8 CAPLUS

CN Glycine, N-[1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylphenylacetyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 471245-85-9 CAPLUS


CN Glycine, N-[1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylphenylacetyl]-, (+)- (9CI) (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)

RN 403987-34-8 CAPLUS


CN 1-Piperazineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-  
α-phenyl-, methyl ester (CA INDEX NAME)



RN 403987-43-9 CAPLUS

CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (-)- (CA INDEX NAME)

Rotation (-).




RN 403987-76-8 CAPLUS

CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



IT 378230-92-3P 403987-34-8P 403987-43-9P

403987-76-8P 403987-79-1P 403989-14-0P

403989-79-7P 471245-91-7P 471245-92-8P

471245-93-9P 471245-94-0P 471245-95-1P

471245-96-2P 471245-97-3P 471245-98-4P

471245-99-5P 471246-00-1P 471246-02-3P

471246-03-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

as (preparation of amidomethylpiperidinyl/piperazinyl-aryl-carboxamides

as lipid lowering agents)


RN 378230-92-3 CAPLUS

CN 1-Piperazineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



● HCl

RN 403987-79-1 CAPLUS

CN 1-Piperazineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 403989-14-0 CAPLUS

CN 4-Piperidineacetic acid,  
1-[4-[[1,1'-biphenyl]-2-ylcarbonyl]amino]phenyl]-  
α-phenyl-, methyl ester (CA INDEX NAME)

10580530.trn


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 403989-79-7 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, methyl ester, (+)- (CA INDEX NAME)


Rotation (+).



RN 471245-91-7 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, methyl ester (CA INDEX NAME)

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 471245-92-8 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $\alpha$ -phenyl-, methyl ester compd. with 2-propanol, hydrochloride (1:1:1) (CA INDEX NAME)

CM 1

CRN 403989-89-9  
CMF C37 H40 N2 O3



CM 2


CRN 67-63-0  
CMF C3 H8 O



L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)

RN 471245-93-9 CAPLUS  
CN 4-Piperidineacetic acid, 1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $\alpha$ -phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 471245-94-0 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[[1,1'-biphenyl]-2-ylcarbonyl]amino]phenyl- $\alpha$ -phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 471245-95-1 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, hydrochloride (1:1), (+)- (CA INDEX NAME)

Rotation (+).


L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 471245-96-2 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



RN 471245-97-3 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (-)- (CA INDEX NAME)


Rotation (-).



RN 471245-98-4 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, (+)- (CA INDEX NAME)


Rotation (+).





RN 471245-99-5 CAPLUS

CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, (+)- (CA INDEX NAME)

Rotation (+).

CRN 471246-01-2  
CMF C31 H29 N3 O3


CM 2

CRN 67-63-0  
CMF C3 H8 OCC(O)CRN 471246-03-4 CAPLUS  
CN 1-Piperazineacetic acid,  
4-[4-[[4'-(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-  
 $\alpha$ -phenyl- (CA INDEX NAME)

RN 471246-00-1 CAPLUS

CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, (-)- (CA INDEX NAME)

Rotation (-).





RN 471246-02-3 CAPLUS

CN 1-Piperazineacetic acid,  
4-[4-[[4'-(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-  
 $\alpha$ -phenyl-, compd. with 2-propanol, hydrochloride (1:1:2) (CA INDEX NAME)

CM 1

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2002-408646 Document No. 137-59940 Preparation of biphenylcarboxamides as lipid lowering agents. Meerpoel, Lieven; Backx, Leo Jacobus Jozef (Janssen Pharmaceutica N.V., Belg.) PCT Int. Appl. WO 2002042271 A2, 20020530, 49 pp. DESIGNATED STATES: W, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE', ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR', KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ', PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UC', US, US, VN, YU, ZA, ZW, AM, AZ, BY, EG, KS, MD, RU, TJ, TM, RW, RT, BE', BE, BJ, CF, CG, CH, CI, CM, CI, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT', LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP13316 20011115. PRIORITY: EP 2000-204150 20001121.

GI




AB The title compds. [I]; p1-p3 = 1-3; R<sub>1</sub> = H, alkyl, alkoxy, etc.; R<sub>2</sub> = H, alkyl, alkoxy, halo, CF<sub>3</sub>; R<sub>3</sub> = H, alkyl; R<sub>4</sub> = alkyl, alkoxy, halo, CF<sub>3</sub>; Z = pyrrolidino, piperidino (N-atom attached to Ph ring, etc.); A = bond, (un)substituted alkanediyl; B = H, alkyl, (un)substituted aryl, etc., useful for the treatment of hyperlipidemia, obesity and type II diabetes, were prepared. Thus, reacting N-(4-[(1E)-3-amino-1-propenyl]phenyl)-4'-trifluoromethyl-[1,1'-biphenyl]-2-carboxamide (prepn. given) with Me 2-bromo-2-phenylacetate in the presence of Et<sub>3</sub>N and Bu<sub>4</sub>NI in THF afforded II. The compds. I were tested for inhibition of ApoB secretion and biol. data were given.


IT 432023-21-7P 432023-22-8P 432023-23-9P  
432023-25-1P 432023-26-2P 432023-27-3P  
432023-29-5P 432023-30-8P 432023-31-9P  
432023-33-1P 432023-34-2P 432023-35-3P  
432023-37-5P 432023-38-6P 432023-39-7P  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU

10580530.trn

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);  
 PREP (Preparation); USES (Uses);  
 (prepn. of biphenylcarboxamides as lipid lowering agents)  
 RN 432023-21-7 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylamino], methyl ester (CA INDEX NAME)




RN 432023-22-8 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[methyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]amino], methyl ester (CA INDEX NAME)




L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 432023-27-3 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinylamino], ethyl ester (CA INDEX NAME)




RN 432023-29-5 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylamino], propyl ester (CA INDEX NAME)

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 432023-23-9 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinylamino], methyl ester (CA INDEX NAME)




RN 432023-25-1 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinylamino], ethyl ester (CA INDEX NAME)




RN 432023-26-2 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[methyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]amino], ethyl ester (CA INDEX NAME)

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 432023-30-8 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[methyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]amino], propyl ester (CA INDEX NAME)




RN 432023-31-9 CAPLUS  
 CN Benzenoacetic acid,  $\alpha$ -[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinylamino], propyl ester (CA INDEX NAME)

10580530.trn

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN





RN 432023-33-1 CAPLUS  
CN Benzeneacetamide, N-ethyl- $\alpha$ -[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]amino]- (CA INDEX NAME)




RN 432023-34-2 CAPLUS  
CN Benzenoacetamide, N-ethyl- $\alpha$ -[methyl[1-[4-[(4'-trifluoromethyl)1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyridinylamino- (CA INDEX NAME)

(Continued)




RN 432023-35-3 CAPLUS  
CN Benzeneacetamide, N-ethyl- $\alpha$ -[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]amino] - (CA INDEX NAME)




RN 432023-37-5 CAPLUS  
CN Benzeneacetamide, N-propyl- $\alpha$ -[(1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)-4-piperidinyl]amino]- (CA INDEX NAME)

112 ANSWER 15 OF 20 CARLISI COPYRIGHT 2009 ACS ON STN




RN 432023-38-6 CAPLUS  
 CN Benzenacetamide,  $\alpha$ -[methyl[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-3-pyrrolidinyl]amino]-N-propyl-  
 (CA)



RN 432023-39-7 CAPLUS  
CN Benzenacetamide, N-propyl- $\alpha$ -[(1-[4-[[4'-(trifluoromethyl) [1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)-3-pyrrolidinyl]amino]- (CA INDEX NAME)


(Continued.)



NH CH C NHPI- $\alpha$

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2002:185098 Document No. 136:2476080 Preparation of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcumamides as lipid lowering agents. Meerpoel, Lieven; Roevena, Peter Walter Maria; Backx, Leo Jacobus Jozef; Van der Veken, Louis Jozef Elisabeth; Vieillevooye, Marcel (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2002020501 A2 20020314, 105 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, IM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EF9926 20010827. PRIORITY: EP 2001-203067 20000904.

GI




AB Title compds. [I]; Z1 =  $(\text{CH}_2)_n$ ,  $\text{CH}_2\text{CH}_2\text{O}$ ; n = 1-3; Z2 =  $(\text{CH}_2)_m$ ; m = 1, 2;  
 XI = O,  $\text{CH}_2$ , CO, NH,  $\text{CH}_2\text{O}$ ,  $\text{CH}_2\text{S}$ , bond; X2, X3 = CH, N, C; R1 = H, alkyl;  
 Ar1, Ar2 = (substituted) Ph, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolyl, furyl, thiényl; R2, R3 = alkyl, alkoxy, halo, CF<sub>3</sub>; R4 = alkyl, alkoxy, halo, OH, SH, cyano, NO<sub>2</sub>, alkylthio, polyhaloalkyl, amino, alkylamino, dialkylamino; p:pp = 0-2; pp = 0-3; XI, R4 taken together with Ar1 and Ar2 to which they are attached = fluoren-1-yl, fluoren-4-yl; A = alkanediyl substituted with 1-2 aryl, heteroaryl, cycloalkyl; when X3 = CH, A may also = N substituted with H, alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl; B = H, alkyl, aralkyl, heteroarylalkyl, (substituted) aryl, heteroaryl, etc.], and N-oxides thereof, were prepared. Thus, 4'-trifluoromethylbiphenyl-2-carboxylic acid was stirred 2 h with (COCl)<sub>2</sub> in CH<sub>2</sub>C<sub>12</sub> containing DMF; the resulting mixture was added to a mixture prepared from 4-(4-aminophenyl)- $\alpha$ -Ph-N-(2,2,2-trifluoroethyl)-1-piperazineacetamide (preparation given) and Et<sub>3</sub>N in CH<sub>2</sub>C<sub>12</sub> under ice/salt cooling followed by stirring and reflux for 2 days to give N-[4-(2-oxo-1-phenyl-2-(2,2,2-trifluoroethyl)amino)ethyl]-1-piperazinylphenyl]-4'-trifluoromethyl[1,1'-biphenyl]-2-carboxamide. The latter inhibited microsomal triglyceride transfer protein (MTP) activity with pIC50 = 7.864.


IT 378230-92-3 CAPLUS  
 403987-30-4P 403987-29-1P  
 403987-32-6P 403987-34-8P  
 403987-35-9P 403987-36-0P 403987-37-1P

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 403987-38-2P 403987-39-3P 403987-40-6P  
 403987-41-7P 403987-42-8P 403987-43-9P  
 403987-45-1P 403991-23-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prep. of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcumamides as lipid lowering agents)

RN 378230-92-3 CAPLUS  
 CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 378230-94-5 CAPLUS  
 CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-(2,2,2-trifluoroethyl)-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 403987-29-1 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403987-30-4 CAPLUS  
 CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (1:1) (CA INDEX NAME)

CM 1


CRN 403987-29-1  
 CMF C34 H31 F3 N2 O3

CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 4-Piperidineacetamide,  $\alpha$ -phenyl-N-propyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 403987-31-5  
 CMF C36 H36 F3 N3 O2

CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

RN 403987-34-8 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[4-[[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl-, methyl ester (CA INDEX NAME)




RN 403987-35-9 CAPLUS  
 CN 1-Piperazineacetamide, N-ethyl- $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)


RN 403987-32-6 CAPLUS

10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403987-36-0 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, propyl ester (CA INDEX NAME)




RN 403987-37-1 CAPLUS  
CN 1-Piperazinepropanoic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 403987-38-2 CAPLUS  
CN 1-Piperidineacetamide, N-ethyl- $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 403987-39-3 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[2',4'-difluoro[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403987-40-6 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[[[2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403987-41-7 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[[3',5'-dichloro[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)




RN 403987-42-8 CAPLUS  
CN 1H-1,4-Diazepine-1-acetic acid, hexahydro- $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 403987-43-9 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (-) (CA INDEX NAME)

Rotation (-).

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403987-45-1 CAPLUS  
CN Carbamic acid, phenyl[1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 403991-23-1 CAPLUS  
CN 1-Piperidinepropanoic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-11-4 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2'-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-propyl- (CA INDEX NAME)




RN 403988-12-5 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-fluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-propyl- (CA INDEX NAME)




RN 403988-13-6 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-propyl- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-14-7 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-propyl- (CA INDEX NAME)




RN 403988-15-8 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2-(2-naphthalenyl)benzoyl)amino]phenyl-α-phenyl-N-propyl- (CA INDEX NAME)




RN 403988-16-9 CAPLUS  
CN 4-Piperidineacetamide, α-phenyl-N-propyl-1-[4-[[3'-trifluoromethyl][1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-17-0 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-N-ethyl-α-phenyl- (CA INDEX NAME)




RN 403988-18-1 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 403988-19-2 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-(phenylmethyl)- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-20-5 CAPLUS  
CN 4-Piperidineacetamide, α-phenyl-N-(phenylmethyl)-1-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-21-6 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl-α-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 403988-22-7 CAPLUS  
 CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-propyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)



RN 403988-23-8 CAPLUS  
 CN 1-Piperazineacetamide, N-(1-methylethyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-24-9 CAPLUS  
 CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-2-propen-1-yl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-25-0 CAPLUS

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 1-Piperazineacetamide, N-(2-methylpropyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-26-1 CAPLUS  
 CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-(3-pyridinylmethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-27-2 CAPLUS  
 CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-(phenylmethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403988-28-3 CAPLUS  
 CN 1-Piperazinepropanamide,  $\alpha$ -phenyl-N-propyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-29-4 CAPLUS  
 CN 1-Piperazinepropanamide, N-butyl- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-30-7 CAPLUS  
 CN 1-Piperazinepropanamide, N-pentyl- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-31-8 CAPLUS  
 CN 1-Piperazinepropanamide,  $\alpha$ -phenyl-N-(2,2,2-trifluoroethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403988-32-9 CAPLUS


CN 4-Piperidineacetamide, 1-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)

RN 403988-33-0 CAPLUS


CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-propyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403988-37-4 CAPLUS

CN 1-Piperidineacetamide, N-(2-methylpropyl)- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

RN 403988-38-5 CAPLUS





CN 1-Piperidineacetamide, N-pentyl- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

RN 403988-39-6 CAPLUS

CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-(3-pyridinylmethyl)-4-[4-[(4'-

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)


RN 403988-34-1 CAPLUS  
CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-2-propen-1-yl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)RN 403988-35-2 CAPLUS  
CN 1-Piperidineacetamide, N-cyclopropyl- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)RN 403988-36-3 CAPLUS  
CN 1-Piperidineacetamide, N-butyl- $\alpha$ -phenyl-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)RN 403988-40-9 CAPLUS  
CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-(2-pyridinylmethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)RN 403988-41-0 CAPLUS  
CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-(2,2,2-trifluoroethyl)-4-[4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

RN 403988-39-6 CAPLUS


CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-(3-pyridinylmethyl)-4-[4-[(4'-

## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403988-42-1 CAPLUS  
CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-(phenylmethyl)-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-43-2 CAPLUS  
CN 1-Piperidineacetamide, N, $\alpha$ -diphenyl-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403988-44-3 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-chlorophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)




RN 403988-45-4 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3',4'-dichlorophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403988-46-5 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-chlorophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403988-49-8 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-aminophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-47-6 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-50-1 CAPLUS  
CN 4-Piperidineacetamide, 4-Piperidineacetamide, N-ethyl-1-[4-[(3'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-48-7 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3',4'-dichlorophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-51-2 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-chlorophenyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-52-3 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(4'-fluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-53-4 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(4'-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-54-5 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-55-6 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(2-(2-naphthalenyl)benzoyl)amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-56-7 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl- $\alpha$ -phenyl-1-[4-[(3'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 403988-57-8 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-amino[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 403988-58-9 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 403988-60-3 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-chlorophenyl)amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 403988-61-4 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2'-methoxy[1,1'-biphenyl]-2-


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403988-64-7 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 403988-65-8 CAPLUS  
 CN 4-Piperidineacetamide,  $\alpha$ -phenyl-N-(phenylmethyl)-1-[4-[(3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- (CA INDEX NAME)




RN 403988-66-9 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403988-67-0 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(2'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-68-1 CAPLUS  
 CN 4-Piperidinesacetamide, 1-[4-[(3'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-69-2 CAPLUS  
 CN 4-Piperidineacetamide, N, $\alpha$ -diphenyl-1-[4-[(2'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-70-5 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(3',4'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-71-6 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(3'-amino[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-72-7 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(3'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403988-73-8 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)



RN 403988-74-9 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(4'-fluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-75-0 CAPLUS  
 CN 4-Piperidineacetamide, 1-[4-[(2'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-N, $\alpha$ -diphenyl- (CA INDEX NAME)


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 403988-76-1 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-77-2 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -diphenyl- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 403988-78-3 CAPLUS  
CN 1H-1,4-Diazepine-1-acetic acid, hexahydro- $\alpha$ -phenyl-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, ethyl ester (CA INDEX NAME)




RN 403988-79-4 CAPLUS  
CN 1H-1,4-Diazepine-1-acetic acid, hexahydro- $\alpha$ -phenyl-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, propyl ester (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403988-80-7 CAPLUS  
CN 1H-1,4-Diazepine-1-acetamide, N-ethylhexahydro- $\alpha$ -phenyl-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (CA INDEX NAME)




RN 403988-81-8 CAPLUS  
CN 1H-1,4-Diazepine-1-acetamide, hexahydro- $\alpha$ -phenyl-N-propyl-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (CA INDEX NAME)




RN 403988-83-0 CAPLUS  
CN 4-Piperidineacetamide,  $\alpha$ -phenyl-N-propyl-1-[4-[(2'-trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403988-85-2 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)



RN 403988-87-4 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(4'-dimethylsilyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)




RN 403988-89-6 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(3'-aminol[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- $\alpha$ -phenyl-N-propyl- (CA INDEX NAME)


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403988-91-0 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(2-(1-naphthalenyl)benzoyl)amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-92-1 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl-1-[4-[(2'-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403988-94-3 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2-(1-naphthalenyl)benzoyl)amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)




RN 403988-95-4 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2-(1-naphthalenyl)benzoyl)amino]phenyl]- $N,\alpha$ -diphenyl- (CA INDEX NAME)



RN 403988-96-5 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[(2-(2-naphthalenyl)benzoyl)amino]phenyl]- $N,\alpha$ -diphenyl- (CA INDEX NAME)




RN 403988-97-6 CAPLUS  
CN 1-Piperazineacetamide,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $N$ -ethyl- $\alpha$ -phenyl- (CA INDEX NAME)




L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403988-98-7 CAPLUS


CN 1-Piperazineacetamide,  $N,\alpha$ -diphenyl-4-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl- (CA INDEX NAME)



RN 403988-99-8 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 403988-00-4 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-, phenylmethyl ester (CA INDEX NAME)




RN 403988-01-5 CAPLUS

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


CN 1-Piperazineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, methyl ester (CA INDEX NAME)



RN 403989-02-6 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)



RN 403989-03-7 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $N,\alpha$ -diphenyl- (CA INDEX NAME)




RN 403989-04-8 CAPLUS  
CN 1-Piperazineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, 2-propen-1-yl ester (CA INDEX NAME)


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)




RN 403989-05-9 CAPLUS  
CN 1-Piperazineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-, phenylmethyl ester (CA INDEX NAME)




RN 403989-06-0 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-N-2-propen-1-yl- (CA INDEX NAME)



RN 403989-07-1 CAPLUS  
CN 1-Piperidineacetamide,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-N-  
ethyl-α-phenyl- (CA INDEX NAME)




RN 403989-08-2 CAPLUS

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
CN 1-Piperazineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-, phenyl ester, hydrochloride (1:2) (CA INDEX NAME)


●2 HCl

RN 403989-09-3 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl-, phenylmethyl ester (CA INDEX  
NAME)




RN 403989-10-6 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-propen-1-yl ester (CA INDEX  
NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403989-11-7 CAPLUS  
CN 1-Piperidineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-, phenylmethyl ester (CA INDEX NAME)



RN 403989-12-8 CAPLUS  
CN 1-Piperidineacetic acid,  
4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-, 2-propen-1-yl ester (CA INDEX NAME)




RN 403989-14-0 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl-  
α-phenyl-, methyl ester (CA INDEX NAME)




L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403989-15-1 CAPLUS  
CN 1-Piperazineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-  
biphenyl]-2-yl]carbonyl]amino]phenyl-, phenyl ester, hydrochloride  
(1:2) (CA INDEX NAME)



●2 HCl

RN 403989-16-2 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-  
yl)carbonyl]amino]phenyl-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-17-3 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-  
yl)carbonyl]amino]phenyl-N-ethyl-α-phenyl- (CA INDEX NAME)


## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)




RN 403989-18-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 403989-19-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-N,  $\alpha$ -diphenyl- (CA INDEX NAME)




RN 403989-20-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-N-2-propen-1-yl- (CA INDEX NAME)




L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 403989-29-7 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, phenylmethyl ester (CA INDEX NAME)




RN 403989-30-0 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, phenyl ester (CA INDEX NAME)




RN 403989-31-1 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]- $\alpha$ -phenyl-, 2-propen-1-yl ester (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
RN 403989-26-4 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]-, phenylmethyl ester (CA INDEX NAME)




RN 403989-27-5 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]-, phenyl ester (CA INDEX NAME)




RN 403989-28-6 CAPLUS  
CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[(4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403989-32-2 CAPLUS  
CN 4-Piperidineacetic acid,  
1-[4-[(1,1'-biphenyl)-2-ylcarbonyl]amino]phenyl]-N-ethyl- $\alpha$ -phenyl-




RN 403989-33-3 CAPLUS  
CN 4-Piperidineacetic acid, N-ethyl- $\alpha$ -phenyl-1-[4-[(4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 403989-36-6 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[5-methyl-4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl-, methyl ester (CA INDEX NAME)




RN 403989-37-7 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[5-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-38-8 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-39-9 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[3-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-43-5 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[4-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-44-6 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[5-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-45-7 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[4,5-dimethoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-40-2 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[3-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-41-3 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-42-4 CAPLUS  
CN 1-Piperazineacetic acid, 4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-46-8 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[4-[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-47-9 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[4-[[4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-48-0 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[4-[[3-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-49-1 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[4-[[3-methyl-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-  
α-phenyl- (CA INDEX NAME)




RN 403989-50-4 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[4-[[4-methyl-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-  
α-phenyl- (CA INDEX NAME)




RN 403989-51-5 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[[4-chloro-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-N-ethyl-α-phenyl- (CA INDEX NAME)




RN 403989-52-6 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[[5-chloro-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-N-ethyl-α-phenyl- (CA INDEX NAME)




RN 403989-54-8 CAPLUS  
CN 1-Piperazineacetamide, 4-[4-[[4,5-dimethoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-N-ethyl-α-phenyl- (CA INDEX NAME)




RN 403989-55-9 CAPLUS  
CN 4-Piperidineacetic acid, α-phenyl-1-[4-[[4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 403989-56-0 CAPLUS  
CN 1-Piperazineacetic acid, 4-[3,5-difluoro-4-[[4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-α-phenyl-, methyl ester (CA INDEX NAME)



RN 403989-57-1 CAPLUS  
CN 1-Piperazineacetic acid, 4-[2-chloro-4-[[4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-α-phenyl-, methyl ester (CA INDEX NAME)



RN 403989-58-2 CAPLUS  
CN 1-Piperazineacetic acid, α-phenyl-4-[[3-(trifluoromethyl)-4-((4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)carbonyl)phenyl]amino]phenyl-, methyl ester (CA INDEX NAME)




RN 403989-59-3 CAPLUS  
CN 1-Piperazineacetic acid, 4-[3-chloro-4-[[4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-α-phenyl-, methyl ester (CA INDEX NAME)

## 10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 403989-60-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[3-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)




RN 403989-61-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[3,5-dimethyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 403989-62-8 CAPLUS

CN 1-Piperazineacetic acid, α-phenyl-4-[[2-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 403989-63-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 403989-64-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[3-fluoro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl-, methyl ester (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)




RN 403989-66-2 CAPLUS

CN 1-Piperazineacetamide, 4-[3-chloro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-N-ethyl-α-phenyl- (CA INDEX NAME)




RN 403989-65-1 CAPLUS

CN 1-Piperazineacetamide, 4-[2-chloro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-N-ethyl-α-phenyl- (CA INDEX NAME)



RN 403989-67-3 CAPLUS

CN 1-Piperazineacetamide, N-ethyl-4-[[3-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-68-4 CAPLUS


CN 1-Piperazineacetamide, 4-[3,5-dimethyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-N-ethyl-α-phenyl- (CA INDEX NAME)

10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 403989-69-5 CAPLUS  
CN 1-Piperazineacetamide, N-ethyl-α-phenyl-4-[2-(trifluoromethyl)-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 403989-70-8 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-71-9 CAPLUS  
CN 1-Piperazineacetamide,  
N-ethyl-4-[3-fluoro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
RN 403989-74-2 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 403989-75-3 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 403989-76-4 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1-ethylpropyl ester (CA INDEX NAME)




RN 403989-77-5 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1-ethylbutyl ester (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
biphenyl]-2-yl]carbonyl]amino]phenyl]-α-phenyl- (CA INDEX NAME)




RN 403989-72-0 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 3-methyl-2-buten-1-yl ester (CA INDEX NAME)




RN 403989-73-1 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 3-phenylpropyl ester (CA INDEX NAME)



L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-propyn-1-yl ester (CA INDEX NAME)



RN 403989-78-6 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 3-methylbutyl ester (CA INDEX NAME)



RN 403989-79-7 CAPLUS  
CN 1-Piperidineacetic acid, α-phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



10580530.trn


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)

RN 403989-94-6 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).




RN 403989-95-7 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, methyl ester, (-)- (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)

Rotation (-).



RN 403989-96-8 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, ethyl ester (CA INDEX NAME)



RN 403989-97-9 CAPLUS


CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 3-methyl-2-buten-1-yl ester (CA INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)


RN 403989-98-0 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 3-phenylpropyl ester (CA INDEX NAME)



RN 403989-99-1 CAPLUS


CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 1-ethylpropyl ester (CA INDEX NAME)



RN 403990-00-1 CAPLUS


CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-propyn-1-yl ester (CA INDEX NAME)




RN 403990-01-2 CAPLUS

CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 3-methylbutyl ester (CA INDEX NAME)



RN 403990-02-3 CAPLUS


CN 4-Piperidineacetic acid,  $\alpha$ -phenyl-1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl-, 2-phenylethyl ester (CA INDEX NAME)




## 10580530.trn

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403990-04-5 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxamide,  
N-[4-[(4-[(ethylamino)carbonyl]phenylamino)-  
1-piperidinyl]phenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 403990-06-7 CAPLUS  
CN 4-Piperidineacetamide,  $\alpha$ -(4-fluorophenyl)-N-(phenylmethyl)-1-[4-  
[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA  
INDEX NAME)




RN 403990-07-8 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-  
y1]carbonyl]amino]phenyl]- $\alpha$ -(4-fluorophenyl)-N-(phenylmethyl)- (CA  
INDEX NAME)

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403990-08-9 CAPLUS  
CN 4-Piperidineacetamide, N-ethyl- $\alpha$ -(4-fluorophenyl)-1-[4-[[4'-  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)- (CA INDEX  
NAME)



RN 403990-09-0 CAPLUS  
CN 4-Piperidineacetamide, 1-[4-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-2-  
y1]carbonyl]amino]phenyl]-N-ethyl- $\alpha$ -(4-fluorophenyl)- (CA INDEX  
NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 403990-10-3 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(2-chlorophenyl)-4-[[4'-  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)-, methyl  
ester (CA INDEX NAME)




RN 403990-11-4 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(2,4-dichlorophenyl)-4-[[4'-  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl)-, methyl  
ester (CA INDEX NAME)


L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 403990-12-5 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(3-chlorophenyl)-4-[[4'-  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl  
ester (CA INDEX NAME)




RN 403990-13-6 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(4-bromophenyl)-4-[[4'-  
(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl  
ester (CA INDEX NAME)




RN 403990-14-7 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(4-chlorophenyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 403990-15-8 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -(4-chlorophenyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



RN 403990-16-9 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 2-phenylethyl ester (CA INDEX NAME)




RN 403990-17-0 CAPLUS  
CN 1-Piperazineacetamide,  $N$ -ethyl-4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)




RN 403990-18-1 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester, (-) (CA INDEX NAME)

Rotation (-).




RN 403990-19-2 CAPLUS  
CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester, (+) (CA INDEX NAME)


Rotation (+).



RN 403990-20-5 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -2-pyridinyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 403990-23-8 CAPLUS  
CN 4-Piperidineacetamide,  $N$ ,  $\alpha$ -diphenyl-1-[4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




IT 403987-79-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcrooxamides as lipid lowering agents)

RN 403987-79-1 CAPLUS

CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 273727-30-3P 403987-75-7P 403987-76-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of piperidinyl-, piperazinyl-, and homopiperazinylpolyarylcrooxamides as lipid lowering agents)

RN 273727-30-3 CAPLUS

CN 1-Piperazinecarboxylic acid,  
4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




● HCl



RN 403987-75-7 CAPLUS

CN 1-Piperazinepropanoic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)





RN 403987-76-8 CAPLUS

CN 1-Piperidineacetic acid,  $\alpha$ -phenyl-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2001-935407 Document No. 136:537680 Preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors. Daugan, Alain Claude-Marie (Glaxo Group Ltd., UK; Kirilovsky, Jorge Eduardo). PCT Int'l Appl'n WO 2001097810 A2 20011227, 78 pp. DESIGNATED STATES: W1, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SB, SG, SI, SK, SL, TT, TR, TZ, UA, UG, US, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RO, TU, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: FIXXD2. APPLICATION: WO 2001-EP6242 20010601. PRIORITY: GB 2000-13378 20000601.

GI




AB The title compds. [I]; A = N, CH; X = alkylene, O, S, SO, etc.; Z = a bond, (un)substituted alkylene, optionally containing one double bond; R<sup>1</sup> = H, perfluoroalkyl, aryl, etc.; Y = a bond, O, alkylene, etc.; R<sup>2</sup> = (un)substituted Ph, cycloalkyl, heterocyclyl; R<sup>3</sup> = H, halo, alkyl, etc., useful as microsomal triglyceride transfer protein (MTP) inhibitors for treating obesity and post-prandial hyperlipemia, were prepared and formulated. Thus, amidation of 4-(4-(3-cyanobenzyl)-piperazin-1-yl)phenylamine with 4'-trifluoromethylbiphenyl-2-carboxylic acid (preps. of both reactants were given) in the presence of HOBE, EDCI and Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> afforded II which showed IC<sub>50</sub> of 0.9 nM in human MTP assay.


IT 273726-55-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors)

10580530.trn

L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 273726-55-9 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl-, ethyl ester (CA INDEX NAME)




IT 273726-50-4P 273726-51-5P 273726-52-6P  
 273726-53-7P 273726-95-7P 273726-96-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors)  
 RN 273726-50-4 CAPLUS  
 CN 1-Piperazineacetamide, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 273726-51-5 CAPLUS  
 CN 1-Piperazineacetamide,  
 4-[4-[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)

L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 273726-96-8 CAPLUS  
 CN 1-Piperazineacetamide, N-[(1,1'-biphenyl)-3-ylmethyl]-4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)




IT 273727-30-3P 273727-31-4P 273727-32-5P  
 273727-33-6P 273727-34-7P 273727-36-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors)  
 RN 273727-30-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 273726-52-6 CAPLUS  
 CN 1-Piperazineacetamide,  
 4-[4-[[6-methyl-4'-(1-methylethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 273726-53-7 CAPLUS  
 CN 1-Piperazineacetamide, 4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)




RN 273726-95-7 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl- (CA INDEX NAME)


L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 273727-31-4 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[5-methyl-4'-(1-methylethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-32-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-33-6 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-y1]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-34-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[4-[[6-methyl-4-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 273727-36-9 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-46-1 CAPLUS  
CN 1-Piperidinocarboxylic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-



L12 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
2001:923708 Document No. 136:537650 Preparation of bioisosteric benzamide derivatives and their use as apoB-100 secretion inhibitors. bodic, Nerina (Glaxo Group Limited, UK). PCT Int. Appl. WO 2001096327 A1 20011220, 59 pp., DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UR, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXKD2. APPLICATION: WO 2001-EF6243 20010601. PRIORITY: GB 2000-13383 20000601.

GI




AB The title compds. [I; A = N or CH; U = a direct link, C1-4 alkylene, C0-4 alkyleneoxy-C0-4 alkylene; V = N, CH<sub>2</sub>; X = (i) (un)substituted C1-6 alkylene optionally containing one or two double bonds, (ii) O, SO<sub>2</sub>, or SO, (iii) C1-6 alkylene carboxyl, C1-6 alkylene sulfonyl, or C1-6 alkylene thioxo, (iv) C2-6 alkyleneoxy, C2-6 alkylene thio, or C2-6 alkylene(NH or N-C1-6 alkylamino), and (v) C1-6 alkylene carboxy, C1-6 alkylene thioamido, C1-6 alkylene(N-H or N-C1-6 alkylcarbamido), etc.; Z = a direct link or (un)substituted C1-6 alkylene optionally containing one double bond; R<sup>1</sup> is selected from the following groups: (i) hydrogen or C1-3 perfluoroalkyl, (ii) C6-10 aryl, C3-8 cycloalkyl and fused benz derivs. thereof, C7-10 polycycloalkyl, C4-8 cycloalkyl, or a C7-10 polycycloalkenyl, (iii) a saturated, partially unsatd., or aromatic monocyclic or polycycloalkenyl heterocycl, etc.; Y = a direct bond, O, C1-6 alkylene, oxy-C1-6 alkylene, etc.; R<sup>2</sup> = (un)substituted Ph, C3-8 cycloalkyl, or a saturated, partially unsatd., or aromatic and monocyclic heterocycl; R<sup>3</sup> = (i) hydrogen or C1-3 perfluoroalkyl, (ii) Ph or a saturated, partially unsatd. or aromatic monocyclic heterocycl, (iii) cyano, hydroxycarbonyl, C1-6 alkoxy carbonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, or C1-6 dialkylaminocarbonyl, etc.] or physiol. acceptable salts, solvates, or derivs. thereof are prepared. These compds. inhibit hepatic production of apoprotein B-100 (apoB-100) and microsomal triglyceride transfer protein (MTP) and intestinal production of chylomicrons or apoprotein B-48 (apoB-48) and MTP and are useful for treating conditions ameliorated by an apoB-100 and/or MTP inhibitors. These compds. are useful in the treatment of atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus (NIDDM), coronary heart diseases, and obesity. They also lower serum lipid levels, cholesterol and/or triglycerides, and are of use in the

L12 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
treatment of hyperlipidemia, postprandial hyperlipidemia, mixed dyslipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia. Thus, to a soln. of 300 mg 4'-isopropyl-6-methylbiphenyl-2-carboxylic acid [2-(piperazinyl)pyridin-5-yl]amide (prep. given) in 20 mL THF contg. triethylamine (0.12 mL) was added 120 mg 2-bromoacetamide and the mixt. was heated under reflux during 4 h to give 130 mg 4'-isopropyl-6-methylbiphenyl-2-carboxylic acid [2-(4-carbamoylmethyl)piperazin-1-yl]pyridin-5-yl]amide (II). II and 4',6-diisopropylbiphenyl-2-carboxylic acid [2-(4-carbamoylmethyl)piperazin-1-yl]pyridin-5-yl]amide showed IC50 of 0.3 and <0.1 μg/mL, resp., against 3H-triglycer transfer onto acceptor liposomes contg. biotinylated phosphatidylethanolamine and phosphatidylcholine.


IT 381707-07-9 4',6-Diisopropylbiphenyl-2-carboxylic acid N-[2-(4-tert-butyloxycarbonylpiperazin-1-yl)pyridin-5-yl]amide RL: RCT (Reactant); SPP (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate); preparation of bioisosteric benzamide derivs. as apoB-100 and/or microsomal triglyceride transfer protein secretion inhibitors

RN 381707-07-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 381707-38-6 CAPLUS  
CN 1-Piperazineacetamide, 4-[5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 381707-42-2 CAPLUS  
CN 1-Piperazineacetamide, 4-[5-[[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 381707-46-6 CAPLUS  
CN 1-Piperazineacetamide, 4-[5-[[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]- (CA INDEX NAME)



L12 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
2001:886090 Document No. 136:200890 Preparation of

N-(piperazinylphenyl)biphenylcarboxamides as inhibitors of MTP and production of apoB-100. Daugan, Alain Claude-Marie (Glaxo Group Ltd.,

UK; Dodic, Nerina. PCT Int. Appl. WO 2001092241 A1 20011206, 41 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,  
BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,  
GH, GM, HR, HV, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI,  
CM, CY, DE, DK, FI, FR, GA, GB, GR, IE, IT, LG, MC, ML, MR, NE, NL,  
PT, SE, SN, TD, TG, TR, TR. (English). CODEN: PIXXDZ. APPLICATION: WO  
2001-EP6244 20010603 PRIORITY: GB 2000-13346 20000601.

AB R1212CONNH2122CHR3K4 [I; R1 = CF3 or CHMe2; R2 = (un)substituted Ph,  
-heteraryl, CONH2, Et, CH2CH2; R4 = cyano, Bz, alkoxy carbonyl,  
heteraryl(methyl), etc.; Z = (un)substituted 1,2-phenylene; Z1 =  
1,4-phenylene throughout; Z2 = piperazine-1,4-diyil throughout] were  
prepared

Thus, 2-(F3CZ1)C6H4CONH2Z2R (II; R = H) was N-alkylated by PhCHMeBr to  
give II (R = CHMePh). Data for biol. activity of I were given.


IT 378230-92-3P 378230-93-4P 378230-94-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(preparation of N-(piperazinylphenyl)biphenylcarboxamides as  
inhibitors of

MTP and production of apoB-100)


RN 378230-92-3 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 378230-93-4 CAPLUS  
CN 1-Piperazineacetic acid,  $\alpha$ -phenyl-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 378230-94-5 CAPLUS  
CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-(2,2,2-trifluoroethyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 378230-95-6 CAPLUS  
CN 1-Piperazineacetamide,  $\alpha$ -phenyl-N-(2-pyridinylmethyl)-4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




L12 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 378231-12-0P 378231-13-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of N-(piperazinylphenyl)biphenylcarboxamides as inhibitors of MTP and production of apoB-100)


RN 378231-12-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[4',6-bis(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

NAME)




RN 378231-13-1 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[[6-(1-methylethyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 2000:384166 Document No. 133:307400 Preparation of benzamides as ApoB-100 secretion inhibitors. Daugan, Alain Claude-marie (Glaxo Group Limited, UK). PCT Int. Appl. WO 2000032582 A1 20000608, 94 pp. DESIGNATED STATES: AE: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, T2, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; BW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP9320 19991201. PRIORITY: GB 1998-26412 19981203.

GI



I




II


AB The title compds. [I]; A = N, CH; X = (un)substituted alkylene (optionally containing one or two double bonds), O, SO<sub>2</sub>, etc.; Z = a direct link, (un)substituted alkylene (optionally containing one double bond); R1 = H, perfluoroalkyl, aryl, etc.; Y = a direct or oxy link, alkylene, etc.; R2 = (un)substituted Ph, cycloalkyl, heterocyclyl; R3 = H, halo, alkyl, etc.), useful in the treatment of conditions mediated by ApoB-100 regulation, were prepared and formulated. Thus, reacting 4-[4-(3-cyanobenzyl)piperazin-1-yl]phenylamine with 4'-trifluoromethylbiphenyl-2-carboxylic acid (preps. given) in the presence of HOEt, Et<sub>3</sub>N and EDCI in CH<sub>2</sub>C<sub>2</sub>I afforded benzamide II which

L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 showed IC<sub>50</sub> of 13 nM against ApoB-100 and ApoA-1 secretion.  
 IT 273726-55-9P 273726-95-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of benzamides as ApoB-100 secretion inhibitors)

RN 273726-55-9 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 273726-95-7 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




IT 273726-50-4P 273726-51-5P 273726-52-6P  
 273726-53-7P 273726-96-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of benzamides as ApoB-100 secretion inhibitors)

RN 273726-50-4 CAPLUS  
 CN 1-Piperazineacetamide, 4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)


L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 273726-51-5 CAPLUS  
 CN 1-Piperazineacetamide,  
 4-[4-[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 273726-52-6 CAPLUS  
 CN 1-Piperazineacetamide,  
 4-[4-[[6-methoxy-4'-(1-methylethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 273726-53-7 CAPLUS  
 CN 1-Piperazineacetamide, 4-[4-[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX NAME)


10580530.trn

L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)




RN 273726-96-8 CAPLUS  
CN 1-Piperazineacetamide, N-[(1,1'-biphenyl]-3-ylmethyl)-4-[4-[[[4'-  
(trifluoromethyl) [1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (CA INDEX  
NAME)




IT 273727-30-3P 273727-31-4P 273727-32-5P  
 273727-33-6P 273727-34-7P 273727-36-9P  
 273727-46-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of benzamides as ApoB-100 secretion inhibitors)  
 RN 273727-30-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid,  
 4-[4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-  
 yl)carbonylamino]phenyl]-1,1-dimethyllethyl ester (CA INDEX NAME)



RN 273727-34-7 CAPLUS  
CN 1-Fiperazinecarboxylic acid, 4-[4-[[[6-methyl-4'-(1-methylethyl)biphenyl]-2-yl]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA  
INDEX  
NAME)




RN 273727-36-9 CAPLUS  
 CN 1-Piperazinecarboxylic acid,  
 4-[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-  
 yl]carbonylaminobenzyl]-1,1-dimethylethyl ester (CA INDEX NAME)




RN 273727-46-1 CAPLUS  
CN 1-Piperidinecarboxylic acid,  
4-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-

L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN


(Continued)



RN 273727-31-4 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-methyl-4'-(1-methylethyl)biphenyl]-2-yl]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA INDEX  
NAME)




RN 273727-32-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[4-[[[6-methoxy-4'-(1-methylethyl)biphenyl]-2-yl]carbonyl]amino]phenyl-, 1,1-dimethylethyl ester (CA  
INDEX  
NAME)



BN 273727-33-6 CAPLUS


L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
y1]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



*γ*-Carboxyjaminophenyl-*α,α*-dimethyl-*β*-ester (CH INDEX VIII)

10580530.trn

=>  
Uploading C:\Program Files\Stnexp\Queries\10580530-9999.str



chain nodes :

13 14 16 17 22 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 24

ring/chain nodes :

15 20 21

10580530.trn

Node 16: Limited

C,C3-10

O,OO

S,SO

N,N0-3

Node 17: Limited

C,C4-5


N,N1-2

L13           STRUCTURE UPLOADED

=> d 113

L13 HAS NO ANSWERS

L13           STR



10580530.trn

provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7  
DICTIONARY FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> s 113
SAMPLE SEARCH INITIATED 18:42:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1589 TO ITERATE
```

```
100.0% PROCESSED 1589 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01
```

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

10580530.trn

=> file caplus  
FILE 'CAPLUS' ENTERED AT 18:43:31 ON 06 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 May 2009 VOL 150 ISS 19  
FILE LAST UPDATED: 5 May 2009 (20090505/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN  
 2005:564639 Document No. 143:780930 Preparation of N-aryl piperidine substituted biphenylcarboxamides as ApoB inhibitors. Meerpoel, Lieven; Vrielenvoye, Marcel (Janssen Pharmaceutica N. V., Belg.). PCT Int. Appl. WO 2005058824 A2 20050630, 46 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXKD2. APPLICATION: WO 2004-BF53280 20041206. PRIORITY: EP 2003-104601 20031209.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = H, alkyl, halo, etc.; R2 = H, alkyl, halo, etc.; R3 = H, alkyl; R4 = H, alkyl, halo; n = 0-1; X = C and Q is C or X = N and Q is O; R = C or X = C and Q is N; W = C, N; Y = O, NR6; R6 = H, alkyl; m = 0-2; Z = O, NH; R7 = H, (un)substituted alkyl, aryl, etc.; R8 = H, alkyl; R9 = H, alkyl, (un)substituted Ph, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed. Thus, e.g., II was prepared by coupling of 4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylic acid with 1-(4-aminophenyl)-4-piperidine acetic acid Et ester followed by hydrolysis and subsequent coupling with 2-(ethoxycarbonyl)piperidine. The activity of I was evaluated by quantifying the secretion of ApoB using liquid scintillation counting and it was revealed that compds. of the invention possessed pIC50 values in the range of <6 up to 8.22. I should prove useful in the treatment of hyperlipidemia, obesity and type II diabetes. Pharmaceutical compns. comprising I are disclosed.

IT 856000-35-6P 856000-39-0P 856000-53-8P  
 856000-54-9P 856000-55-0P 856000-57-2P  
 856000-59-4P 856000-61-8P 856000-63-0P  
 856000-65-2P 856000-84-5P 856000-87-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-aryl piperidine substituted biphenylcarboxamides as

Apob (inhibitors)


RN 856000-35-6 CAPLUS

CN 2-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester (CA INDEX NAME)

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 856000-39-0 CAPLUS  
 CN 3-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester (CA INDEX NAME)



RN 856000-53-8 CAPLUS  
 CN 2-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 856000-54-9 CAPLUS  
 CN 2-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, methyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 856000-55-0 CAPLUS  
 CN 3-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 856000-57-2 CAPLUS  
 CN 3-Piperidincarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-59-4 CAPLUS  
 CN D-Proline, 1-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10580530.trn


L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 856000-61-8 CAPLUS  
CN L-Proline, 4-hydroxy-1-[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester, (4R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-63-0 CAPLUS  
CN L-Proline, 4-hydroxy-1-[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester, (4R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 856000-65-2 CAPLUS  
CN L-Proline, 4-hydroxy-1-[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, methyl ester, (4S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856000-84-5 CAPLUS  
CN L-Proline, 1-[[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

(Continued)



RN 856000-87-8 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[2-[1-[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]-4-piperidinyl]acetyl]-, ethyl ester  
(CA INDEX NAME)



10580530.trn

=> FIL STNGUIDE  
FILE 'STNGUIDE' ENTERED AT 18:44:21 ON 06 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 1, 2009 (20090501/UP).

=>